A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis
Phase: PHASE3
Conditions: Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
Sponsor: Radius Health, Inc.

Radius Health, Inc. (RADIUS) 
22 Boston Wharf Road, 7th Floor 
Boston, MA 02210 USA 
(617) 551-4000
Abaloparatide-SC 
CLINICAL STUDY PROTOCOL: BA058-05-019 
A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate 
the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men with Osteoporosis 
This study will be conducted according to the protocol and in compliance with Good Clinical Practice, the 
ethical principles stated in the Declaration of Helsinki, and other applicable regulatory requirements. 
Document Type: 
Clinical Study Protocol 
EudraCT Number:  
2017-004220-30  
IND Number: 
73,176 
Version Number: 
Amendment 6 (30 March 2021) 
Development Phase: 
3  
Study Site: 
Multicenter; international  
Protocol Version History 
Version Number 
Version Date 
Original 
12 October 2017 
Amendment 1 
09 January 2018 
Amendment 2 
30 October 2018 
Amendment 3 
06 June 2019 
Amendment 4 
10 December 2019 
Amendment 5 
02 October 2020 
Confidentiality Statement 
The information in this document contains trade secrets and/or commercial information that are privileged 
or confidential and may not be disclosed unless such disclosure is required by applicable law or 
regulations. In any event, persons to whom the information is disclosed must be informed that the 
information is privileged or confidential and may not be further disclosed by them. These restrictions on 
disclosure will apply equally to all future information supplied to you which is indicated  
as privileged or confidential. 
NCT#: NCT03512262

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 2 of 81 
STATEMENT OF COMPLIANCE 
The study will be carried out in accordance with Good Clinical Practice (GCP), as required by 
the International Council for Harmonisation of Technical Requirements of Pharmaceuticals for 
Human Use (ICH) GCP E6 (R2) guidance. 
In addition, I have read the clinical study protocol with the title of: A Randomized, Double-blind, 
Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of 
Abaloparatide-SC for the Treatment of Men with Osteoporosis, Amendment 6 dated 30 March 
2021, and agree to the following conditions: 
• To conduct this study in accordance with the design and provisions of this clinical 
study protocol. 
• To await Institutional Review Board/Independent Ethics Committee (IRB/IEC) 
approval for the protocol and informed consent (IC) before initiating enrollment into 
the study. If approval is suspended or terminated by the IRB/IEC the principal 
investigator will notify the Sponsor immediately. 
• To ensure that the requirements for obtaining IC are met and to obtain IC from 
subjects before their enrollment into the study. 
• To provide sufficient and accurate financial disclosure and update information if any 
relevant changes occur during the investigation and for 1 year following the 
completion of the study. 
• To collect and record data as required by this protocol into the case report form 
(CRF). 
• To maintain the confidentiality of all information received or developed in connection 
with this protocol. 
• To conduct this study in accordance with the ICH GCP guideline, the Declaration of 
Helsinki, and all applicable regulatory requirements. 
• To permit study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s) by providing direct access to source data/documents. 
• To maintain study documentation for the period of time required. 
• To report all adverse events (AEs) within the specified timeframe to Radius Health, 
Inc. (RADIUS) or their designee. 
• To report all serious AEs/incidents within 24 hours after becoming aware of the event 
to the Contract Research Organization and enter the data into the Electronic Data 
Capture system. 
• To adhere to the publication policy of RADIUS Health, Inc. for data collected during 
this study. 
 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 3 of 81 
 
 
 
 
Signature of Principal Investigator 
 
 
 
 
 
Date 
Print Name 
 
Site Number 
 
 
 
 
 
 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 4 of 81 
 
 
TABLE OF CONTENTS 
STATEMENT OF COMPLIANCE .................................................................................................2 
TABLE OF CONTENTS .................................................................................................................4 
LIST OF TABLES ...........................................................................................................................8 
LIST OF FIGURES .........................................................................................................................8 
PROTOCOL SYNOPSIS ..............................................................................................................12 
1. 
INTRODUCTION ......................................................................................................21 
1.1. 
Background .................................................................................................................21 
1.1.1. 
Disease and Study Drug Background .........................................................................21 
1.1.2. 
Study Drug Development ...........................................................................................22 
1.1.2.1. 
Nonclinical Studies in Male Animals .........................................................................22 
1.1.2.2. 
Clinical Studies ...........................................................................................................23 
1.2. 
Study Rationale ...........................................................................................................25 
1.3. 
Dose Rationale ............................................................................................................25 
2. 
STUDY OBJECTIVES AND ENDPOINTS ..............................................................31 
2.1. 
Primary Objective and Endpoint ................................................................................31 
2.2. 
Secondary Endpoints ..................................................................................................31 
3. 
STUDY DESIGN .......................................................................................................33 
3.1. 
Description of the Study Design .................................................................................33 
4. 
SELECTION OF STUDY POPULATION ................................................................34 
4.1. 
Inclusion Criteria ........................................................................................................34 
4.2. 
Exclusion Criteria .......................................................................................................35 
4.3. 
Participant Withdrawal or Termination ......................................................................37 
4.3.1. 
Reasons for Withdrawal or Termination ....................................................................37 
4.3.2. 
Handling of Participant Withdrawals or Terminations ...............................................38 
4.4. 
Concomitant Medications ...........................................................................................38 
4.5. 
Prohibited Medications ...............................................................................................39 
4.6. 
Premature Termination or Suspension of Study .........................................................39 
4.7. 
Temporary Suspension of Treatment ..........................................................................39 
4.7.1. 
Treatment Algorithm in Subjects Who Develop Hypercalcemia ...............................40 
4.7.2. 
Treatment Algorithm in Subjects Who Develop Hypercalciuria ...............................41 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 5 of 81 
5. 
STUDY DRUG ADMINISTRATION AND MANAGEMENT ...............................43 
5.1. 
Study Medication ........................................................................................................43 
5.1.1. 
Abaloparatide-SC and Placebo ...................................................................................43 
5.1.2. 
Calcium and Vitamin D Supplements ........................................................................43 
5.2. 
Packaging, Labeling and Storage ...............................................................................43 
5.2.1. 
Packaging and Labeling ..............................................................................................43 
5.2.2. 
Storage ........................................................................................................................43 
5.3. 
Treatment Assignment ................................................................................................44 
5.4. 
Dosing and Administration .........................................................................................44 
5.5. 
Treatment Compliance ................................................................................................45 
5.6. 
Drug Accountability ...................................................................................................45 
5.7. 
Unblinding of Study Medication ................................................................................46 
5.7.1. 
Medical Emergency ....................................................................................................46 
6. 
STUDY PROCEDURES AND SCHEDULE ............................................................47 
6.1. 
Study Procedures ........................................................................................................47 
6.1.1. 
Study-Specific Procedures ..........................................................................................47 
6.2. 
Study Schedule ...........................................................................................................47 
6.2.1. 
Schedule of Assessments and Procedures ..................................................................47 
6.2.2. 
Informed Consent Process ..........................................................................................52 
6.2.3. 
Assigning Subject Numbers .......................................................................................52 
6.2.4. 
Subject and Disease Characteristics ...........................................................................52 
6.2.5. 
Screening Period (Visit 1) ..........................................................................................52 
6.2.6. 
Pretreatment Period (Visit 2) ......................................................................................53 
6.2.7. 
Treatment Period ........................................................................................................54 
6.2.8. 
Visit 3 (Day 1) ............................................................................................................54 
6.2.9. 
Visit 4 (Month 1) ........................................................................................................55 
6.2.10. 
Visit 5 (Month 3) ........................................................................................................55 
6.2.11. 
Visit 6 (Month 6) ........................................................................................................56 
6.2.12. 
Visit 7 (Month 9) ........................................................................................................57 
6.2.13. 
Visit 8 (Month 12)/Early Termination Visit ...............................................................57 
6.2.14. 
Visit 9/Safety Follow-up.............................................................................................58 
6.2.15. 
Unscheduled Visit .......................................................................................................58 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 6 of 81 
6.3. 
Vital Signs and Physical Examinations ......................................................................58 
6.4. 
12-Lead Electrocardiogram ........................................................................................59 
6.5. 
Laboratory Evaluations ...............................................................................................59 
6.5.1. 
Clinical Laboratory Evaluations .................................................................................59 
6.5.2. 
Serum Markers of Bone Metabolism ..........................................................................60 
6.5.3. 
Immunogenicity Testing .............................................................................................61 
6.5.4. 
Pharmacokinetic Testing ............................................................................................61 
6.5.5. 
Specimen Preparation, Handling and Storage ............................................................61 
6.6. 
Imaging Procedures ....................................................................................................61 
6.6.1. 
Dual Energy X-ray Absorptiometry ...........................................................................61 
6.6.2. 
Quantitative Computed Tomography .........................................................................62 
6.6.3. 
Clinical and Radiologic Evaluation of Fractures ........................................................62 
6.7. 
Discontinuation from the Study ..................................................................................62 
6.7.1. 
Withdrawal of Consent ...............................................................................................63 
6.7.2. 
Early Study Termination .............................................................................................63 
7. 
ADVERSE EVENT AND SERIOUS ADVERSE EVENT 
DOCUMENTATION .................................................................................................64 
7.1. 
Evaluation of Safety ...................................................................................................64 
7.1.1. 
Adverse Event .............................................................................................................64 
7.1.2. 
Serious Adverse Event ................................................................................................64 
7.1.3. 
Recording an Adverse Event ......................................................................................65 
7.1.3.1. 
Serious and Unanticipated Adverse Device Effects for Abaloparatide-SC ................67 
7.1.4. 
Serious Adverse Event Reporting ...............................................................................67 
7.1.5. 
Device Reporting ........................................................................................................68 
7.1.6. 
Follow-up of Adverse Events .....................................................................................68 
7.1.7. 
Abuse, Misuse, Overdose, or Medication Error .........................................................68 
7.1.8. 
Pregnancy ...................................................................................................................68 
7.1.9. 
Regulatory Agency, Institutional Review Board, Ethics Committee and Site 
Reporting ....................................................................................................................69 
7.2. 
Study Completion and Post-Study Treatment ............................................................69 
7.3. 
Lost to Follow-up .......................................................................................................69 
8. 
STATISTICAL CONSIDERATIONS .......................................................................70 
8.1. 
Statistical and Analytical Plans ..................................................................................70 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 7 of 81 
8.2. 
Statistical Hypotheses .................................................................................................70 
8.3. 
Analysis Datasets ........................................................................................................70 
8.3.1. 
Populations for Analysis .............................................................................................70 
8.4. 
Description of Statistical Methods ..............................................................................70 
8.4.1. 
General Approach .......................................................................................................70 
8.4.2. 
Analysis of the Primary Efficacy Endpoint(s) ............................................................70 
8.4.3. 
Analysis of Secondary Endpoint(s) ............................................................................71 
8.4.4. 
Pharmacokinetic Analyses ..........................................................................................73 
8.4.5. 
Safety Analyses ..........................................................................................................73 
8.4.6. 
Adherence and Retention Analyses ............................................................................74 
8.4.7. 
Baseline Descriptive Statistics ....................................................................................74 
8.4.8. 
Interim Analyses .........................................................................................................75 
8.4.9. 
Additional Subgroup Analyses ...................................................................................75 
8.4.10. 
Multiple Comparison/Multiplicity ..............................................................................75 
8.4.11. 
Tabulation of Individual Response Data ....................................................................75 
8.4.12. 
Exploratory Analyses ..................................................................................................75 
8.5. 
Sample Size Calculation .............................................................................................75 
8.6. 
Measures to Minimize Bias ........................................................................................75 
8.7. 
Enrollment/Randomization/Masking Procedures .......................................................75 
9. 
ADMINISTRATIVE REQUIREMENTS ..................................................................76 
9.1. 
Ethical Considerations ................................................................................................76 
9.2. 
Subject Information and Informed Consent ...............................................................76 
9.3. 
Investigator Compliance .............................................................................................76 
9.4. 
Access to Records .......................................................................................................76 
9.5. 
Subject and Data Confidentiality ................................................................................77 
9.6. 
Research Use of Stored Human Samples, Specimens, or Data ..................................77 
9.7. 
Data Quality Assurance ..............................................................................................77 
9.8. 
Monitoring ..................................................................................................................78 
9.9. 
Data Collection and Management Responsibilities ....................................................78 
9.10. 
Study Records Retention ............................................................................................79 
9.11. 
Publication and Data Sharing Policy ..........................................................................79 
10. 
LITERATURE REFERENCES..................................................................................80 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 8 of 81 
 
LIST OF TABLES 
Table 1: 
Summary of PK Data in Subjects Treated with Abaloparatide-SC 80 µg 
(Pooled Data#) .............................................................................................................26 
Table 2: 
Pooled Treatment-Emergent Adverse Events – Differences Between Male 
and Female Subjects in Phase 1 Studies (BA05805-010, BA05805-010, 
BA05805-011, BA05805-012, and BA05805-014) * .................................................29 
Table 3: 
Schedule of Assessments and Procedures ..................................................................48 
Table 4: 
Schedule for Pharmacokinetic Sample Collections ....................................................51 
Table 5: 
Clinical Laboratory Tests ...........................................................................................60 
 
LIST OF FIGURES 
Figure 1: 
L4 Vertebral Body BMD after 4 Weeks of Treatment in Male Rats ..........................23 
Figure 2: 
PK Concentration over Time in Subjects Treated with Abaloparatide-SC 
80 µg (Pooled Data#) ..................................................................................................27 
Figure 3: 
Study BA058-05-012 – Mean (95% CI) Change from Baseline in Serum 
Calcium over Time by Gender for Abaloparatide 80 µg Treatment (Safety 
Population) ..................................................................................................................28 
Figure 4: 
Study BA058-05-019 Design .....................................................................................33 
Figure 5: 
Treatment Algorithm in Subjects Who Develop Hypercalcemia ...............................42 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 9 of 81 
LIST OF ABBREVIATIONS 
Abbreviation  
Term 
aBMD 
 
Areal bone mineral density 
AE 
 
Adverse event 
AFF 
 
Atypical femoral fracture 
ALT 
 
Alanine aminotransferase  
ANCOVA 
 
Analysis of covariance 
ANOVA 
 
Analysis of variance 
AST 
 
Aspartate aminotransferase  
AUC 
 
Area under the plasma concentration-time curve 
AUC0–∞ 
 
Area under the plasma concentration-time curve from time zero 
to infinity 
AUClast  
 
Area under the plasma concentration-time curve from time zero 
to the time of the last quantifiable concentration 
BMD  
 
Bone mineral density 
BMI 
 
Body mass index  
BP 
 
Blood pressure 
bpm 
 
Beats per minute 
BSAP 
 
Bone-specific alkaline phosphatase 
BUN 
 
Blood urea nitrogen  
BVF 
 
Bone volume fraction 
cAMP 
 
Cyclic adenosine monophosphate 
Cmax 
 
Maximum plasma concentration 
COVID-19 
 
Coronavirus disease 2019 
CPK 
 
Creatine phosphokinase  
CRF 
 
Case report form 
CRO 
 
Contract research organization 
DXA 
 
Dual energy X-ray absorptiometry  
ECG 
 
Electrocardiogram 
eCRF 
 
Electronic case report form 
EDC 
 
Electronic data capture 
EU 
 
European Union 
FDA 
 
Food and Drug Administration 
FRAX 
 
Fracture Risk Assessment  
GCP 
 
Good clinical practice 
GGT 
 
Gamma-glutamyl transpeptidase  
GLP  
 
Good laboratory practice 
Gmean 
 
Geometric mean 
GMP  
 
Good manufacturing practice 
HIPAA 
 
Health Insurance Portability and Accountability Act 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 10 of 81 
Abbreviation  
Term 
HIV 
 
Human immunodeficiency virus 
IB 
 
Investigator's Brochure 
IC 
 
Informed consent 
ICF 
 
Informed consent form 
ICH 
 
International Council for Harmonisation 
IEC 
 
Independent Ethics Committee 
IRB 
 
Institutional Review Board 
IRT 
 
Interactive response technology 
ITT 
 
Intention-to-treat 
IUD 
 
Intrauterine device 
IV 
 
Intravenous 
LDH 
 
Lactate dehydrogenase  
LLN 
 
Lower limit of normal 
LOCF 
 
Last observation carried forward 
MedDRA 
 
Medical Dictionary for Regulatory Activities 
mmHg 
 
Millimeter of mercury 
MMRM 
 
Mixed Model for Repeated Measures 
ONJ 
 
Osteonecrosis of the jaw 
ORX 
 
Orchidectomized 
PI 
 
Principal Investigator 
PK 
 
Pharmacokinetic(s) 
PMM 
 
Pattern-mixture model 
PP 
 
Per-Protocol 
PT 
 
Prothrombin time 
PTH  
 
Parathyroid hormone 
PTHR1 
 
Parathyroid hormone related protein type 1 receptor 
PTHrP  
 
Parathyroid hormone related peptide 
PTT 
 
Partial thromboplastin time  
Q1, Q3 
 
Interquartile range 
QA 
 
Quality assurance 
QCT 
 
Quantitative computed tomography 
QT  
 
Total depolarization and repolarization time 
QTc  
 
Total depolarization and repolarization time corrected with heart 
rate 
R0 
 
Non-G protein-coupled 
RANK 
 
Receptor activator of nuclear factor kappa-B 
RBC  
 
Red blood cell 
RG 
 
G protein-coupled 
rhPTH 
 
Recombinant human parathyroid hormone 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 11 of 81 
Abbreviation  
Term 
SAE 
 
Serious adverse event 
SAP 
 
Statistical Analysis Plan 
SC 
 
Subcutaneous 
s-CTX 
 
Serum carboxy-terminal cross-linking telopeptide of type I 
collagen 
SD 
 
Standard deviation 
SHBG 
 
Sex hormone binding globulin 
sMTS 
 
Solid microstructured transdermal system 
SOC 
 
System organ class 
SOP 
 
Standard operating procedure 
s-PINP 
 
Serum procollagen type I N-terminal propeptide 
SUSAR 
 
Suspected unexpected serious adverse reaction 
t1/2 
 
Apparent terminal phase half-life 
TEAEs 
 
Treatment-emergent adverse events 
tmax  
 
Time to reach maximum plasma concentration following drug 
administration 
TSH 
 
Thyroid stimulating hormone 
UADE 
 
Unanticipated adverse device effect 
ULN 
 
Upper limit of normal 
US 
 
United States 
vBMD 
 
Volumetric bone mineral density 
WHO 
 
World Health Organization 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 12 of 81 
PROTOCOL SYNOPSIS 
Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate 
the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men with Osteoporosis 
Protocol Number: BA058-05-019 
Test Drug: Abaloparatide 80 µg for subcutaneous injection 
Study Objectives and Endpoints 
Objective: The primary objective of this prospective controlled study is to evaluate the efficacy 
and the safety of abaloparatide-subcutaneous (SC) 80 µg per day compared to placebo in men 
with osteoporosis. 
Endpoints 
The primary efficacy endpoint is the percent change from baseline in lumbar spine bone mineral 
density (BMD) at 12 months. 
The key secondary efficacy endpoints are: 
• Percent change from baseline in total hip BMD at 12 months 
• Percent change from baseline in femoral neck BMD at 12 months 
Additional secondary efficacy endpoints are: 
• Percent change from baseline in: 
− Lumbar spine BMD at 3 and 6 months 
− Total hip BMD at 3 and 6 months 
− Femoral neck BMD at 3 and 6 months 
− Ultra-distal radius BMD at 3, 6, and 12 months 
− Distal one-third radius BMD at 3, 6, and 12 months 
• Log ratio of post-baseline over baseline in: 
− Serum procollagen type I N-terminal propeptide (s-PINP) at 1, 3, 6, and 12 
months 
− Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTX) at 1, 
3, 6, and 12 months 
• Proportion of subjects experiencing BMD gains from baseline of > 0%, > 3%, and 
> 6% at the lumbar spine, femoral neck, and total hip at 3, 6, and 12 months 
• Incidence of new clinical fractures at 12 months 
• Proportion of subjects converting from the categories of osteoporosis to osteopenia or 
to normal at 12 months, where: 
− Osteoporosis is defined as lumbar spine or total hip BMD T-score ≤ -2.5.  

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 13 of 81 
− Osteopenia is defined as one of the following: 
o 
Lumbar spine > -2.5 and total hip BMD T-score > -2.5 and < -1.0  
o 
Lumbar spine > -2.5 and < -1.0 and total hip BMD T-score > -2.5 
− Normal is defined as lumbar spine and total hip BMD T-score ≥ -1.0. 
• The percent change in total hip and femoral neck volumetric BMD (vBMD) as 
measured by quantitative CT (QCT) from baseline to 12 months. QCT will be 
performed in a subset of subjects at a selected number of study sites. 
For those subjects who consent to pharmacokinetic (PK) sample collection, the PK endpoints 
are: 
• The plasma concentration of abaloparatide based on sparse PK sampling at the 
following visits: 
− Month 6: postdose PK samples collected 45 minutes (±15 minutes) and 2.5 hours 
(±0.5 hour) after abaloparatide-SC injection 
− Month 9: postdose PK samples collected 20 minutes (±10 minutes) and 4 hours 
(±0.5 hour) after abaloparatide-SC injection 
− Month 12: a predose sample and a postdose sample collected 1.5 hours 
(±0.5 hour) after abaloparatide-SC injection 
The safety endpoints are: 
• Overall safety and tolerability of abaloparatide-SC in men with osteoporosis as 
assessed by adverse events (AE), vital signs, electrocardiograms (ECGs), laboratory 
tests of chemistry and hematology, urinalyses, local tolerance, and presence of 
antibodies 
Subgroup analyses (e.g., age, geography, Fracture Risk Assessment, FRAX [if applicable], prior 
fracture, and baseline BMD, s-PINP, testosterone, and estradiol levels) may be performed and 
will be described in the Statistical Analysis Plan. 
Study Population 
Men aged 40 to 85 years with primary osteoporosis or osteoporosis associated with 
hypogonadism. 
Inclusion Criteria 
1. The subject is a healthy ambulatory male from 40 to 85 years of age (inclusive) with 
primary osteoporosis or osteoporosis associated with hypogonadism. 
2. The subject has a BMD T-score (based on the male reference range as assessed by the 
central imaging vendor) of: 
a. ≤ -2.5 at the lumbar spine (L1–L4) or hip (femoral neck or total hip) by dual energy 
X-ray absorptiometry (DXA); or 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 14 of 81 
b. ≤ -1.5 and with radiologic evidence of vertebral fracture or a documented (radiograph 
films or report) history of low-trauma nonvertebral fracture sustained in the past 5 
years. 
c. Men older than 65 years may be enrolled if they have a BMD T-score ≤ -2.0 even if 
they do not meet the fracture criteria. 
3. The subject is in good general health as determined by medical history and physical 
examination (including vital signs) and is without evidence of a clinically significant 
abnormality in the opinion of the Investigator, or none for which there is a reasonable 
chance of interfering with the subject’s health and/or medical treatment during the study. 
The subject has a body mass index (BMI) of 18.5 to 33, inclusive. The BMI is derived 
from the subject’s height and weight. In the case where a subject’s height cannot be 
adequately assessed (e.g., due to vertebral compression fractures or scoliosis), the subject’s 
historical height (as documented in the subject’s medical record) will be used to derive the 
BMI.  
4. Hypogonadal subjects whose doses of androgens have been stable for at least 12 months 
before randomization are eligible and may continue therapy during the study. 
5. The subject has serum calcium (albumin-corrected), parathyroid hormone (PTH), serum 
phosphorus and alkaline phosphatase, and thyroid stimulating hormone (TSH) values all 
within the normal range during the Screening Period. Any subject with an elevated 
alkaline phosphatase value and who meets all other entry criteria must have a normal 
bone-specific alkaline phosphatase to be enrolled. Any subject with a TSH value outside 
of the normal range must have central laboratory reported T3 and free T4 values within 
the normal ranges to be enrolled. 
6. The subject has serum 25-hydroxyvitamin D values ≥ 20 ng/mL and within the normal 
range. Subjects with serum 25-hydroxyvitamin D levels < 20 ng/ml may be treated with 
vitamin D and retested once during the Screening Period. 
7. The subject’s systolic blood pressure is ≥ 100 and ≤ 155 mmHg, diastolic blood pressure 
is ≥ 40 and ≤ 95 mmHg, and heart rate is ≥ 45 and ≤ 100 bpm (taken sitting or supine). 
Any recorded values outside of these ranges and assessed by the Investigator to be not 
clinically significant must be reviewed with the Medical Monitor and Sponsor for 
approval prior to enrollment. 
8. The subject has no clinically significant abnormality of serum hemoglobin, hematocrit, 
white blood cells and platelets, or usual serum biochemistry: electrolytes, renal function, 
liver function and serum proteins that might be expected to interfere with the subject’s 
health and/or medical treatment during the study. 
9. In subjects who have partners of childbearing potential, the subject and his partner should 
abstain from sexual intercourse, or use highly effective contraceptive measures (e.g., oral 
contraceptive and condom, intrauterine device [IUD] and condom, or diaphragm with 
spermicide and condoms; other forms of contraception must be approved by the Medical 
Monitor) when engaging in sexual intercourse throughout the study, and for at least 90 
days after the last dose of abaloparatide. 
10. The subject has read, understood, and signed the written informed consent form. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 15 of 81 
Exclusion Criteria 
General exclusion criteria: 
1. Presence of abnormalities of the lumbar spine that would prohibit assessment of spinal 
BMD, defined as having at least 2 radiologically evaluable vertebrae within L1–L4 as 
assessed by the central imaging reader. 
Anatomically abnormal vertebrae are excluded if: 
• They are clearly abnormal and non-assessable within the resolution of the system; or 
• There is a more than 1.0 T-score difference between the vertebra in question and 
adjacent vertebrae. 
2. A BMD T-score of ≤ -3.5 at the total hip, femoral neck or lumbar spine based upon the 
male reference range. 
3. Unevaluable hip BMD or subjects who have undergone bilateral hip replacement 
(unilateral hip replacement is acceptable). 
4. Fragility fracture within the past 12 months. 
5. History of severe vertebral fracture or > 2 moderate vertebral fractures. 
6. History of bone disorders (e.g., Paget’s disease) other than osteoporosis. 
7. Subjects with clinical signs of hypogonadism present at screening who plan to initiate 
testosterone replacement. 
8. History of prior external beam or implant radiation therapy involving the skeleton, other 
than radioiodine. 
9. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, 
gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or 
immunologic, emotional and/or psychiatric disturbances to a degree that would interfere 
with the interpretation of study data or compromise the safety of the subject. 
10. History of Cushing’s disease, growth hormone deficiency or excess, hyperthyroidism, 
hypo- or hyperparathyroidism or malabsorptive syndromes within the past year. 
11. History of significantly impaired renal function (serum creatinine > 177 μmol/L or 
> 2.0 mg/dL). If the serum creatinine is > 1.5 and ≤ 2.0 mg/dL, the calculated creatinine 
clearance (Cockcroft-Gault) must be ≥ 37 mL/min. 
12. History of any cancer within the past 5 years (other than basal cell or squamous cancer of 
the skin). 
13. History of osteosarcoma at any time. 
14. Subjects with hereditary disorders predisposing to osteosarcoma. 
15. History of nephrolithiasis or urolithiasis within the past 5 years. 
16. Subjects known to be positive for Hepatitis B, Hepatitis C, human immunodeficiency 
virus (HIV)-1 or HIV-2. Testing is not required in the absence of clinical signs and 
symptoms suggestive of HIV infection or acute or chronic hepatitis. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 16 of 81 
Medication-related exclusion criteria: 
17. Known history of hypersensitivity to any of the test materials or related compounds. 
18. Prior treatment with PTH- or parathyroid hormone related protein (PTHrP)-derived 
drugs, or bone anabolic drugs including abaloparatide, teriparatide, or PTH(1-84). 
19. Prior treatment with intravenous (IV) bisphosphonates at any time or oral 
bisphosphonates within the past 3 years. Subjects who had received a short course of oral 
bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment 
occurred 6 or more months prior to enrollment. 
20. Treatment with fluoride or strontium in the past 5 years or prior treatment with gallium 
nitrate or other bone-acting investigational agents at any time. Limited use of gallium 
citrate/nitrate for diagnostic purposes (i.e., a gallium scan) is not exclusionary. 
21. Prior treatment with calcitonin or tibolone in the past 6 months. 
22. Prior treatment with denosumab within the past 18 months. 
23. Treatment with anticonvulsants that affect vitamin D metabolism (phenobarbital, 
phenytoin, carbamazepine, or primidone) or with chronic heparin within the 6 months 
prior to the Screening Period. 
24. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) 
within the past 90 days.  
25. Daily treatment with oral, intranasal, or inhaled corticosteroids within the 12 months 
prior to the Screening Period. Occasional use of all corticosteroids (for seasonal allergies 
or asthma) is not exclusionary. 
26. Exposure to an investigational drug within the 12 months prior to the Screening Period. 
Lifestyle-related exclusion criteria: 
27. Abnormal nutritional status (as assessed by the Investigator), vitamin D intake of 
≥ 4,000 IU/day or vitamin A intake of ≥ 10,000 IU/day. Short term use of high doses of 
vitamin D to increase endogenous vitamin D levels for study entry is not exclusionary. 
28. Subject is known to consume > 2 alcoholic drinks per day, to use illegal drugs, or to 
abuse tobacco or marijuana (medicinally or recreationally where legal) within 12 months 
of the Screening Period. The Investigator must determine and document use vs. abuse of 
tobacco or marijuana. 
Design and Methodology 
Number of Subjects 
Approximately 225 men will be enrolled into the study. 
Design 
This is a randomized, double-blind, placebo-controlled, Phase 3, multicenter study enrolling 
approximately 225 subjects at approximately 40 study sites designed to evaluate the efficacy and 
safety of abaloparatide-SC 80 µg per day for the treatment of osteoporosis in men. The study will 
consist of a Screening Period (up to 2 months), a Pretreatment Period (1 week), and a Treatment 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 17 of 81 
Period (12 months) with a final visit 1 month after the last dose of study medication (Follow-up 
Visit). Eligible subjects will be randomized, on a 2:1 basis, to receive either abaloparatide-SC 
80 µg per day or matched-SC placebo injections for 12 months to determine the effect of 
abaloparatide on lumbar spine BMD and other bone health-related endpoints. Both groups of 
subjects will undergo protocol-specified procedures (Schedule of Assessments and Procedures, 
Table 3) including BMD and fracture assessments. The study design is presented in the figure 
below. 
Protocol BA058-05-019 Study Design 
 
Study Visits 
All subjects will have clinic visits for study-related procedures at Day 1, Month 1, Month 3, 
Month 6, Month 9, and Month 12, with a Follow-up Visit 1 month after the last dose of study 
medication. For the purposes of this study 1 month is equal to 30 days. 
Treatments Administered 
Eligible subjects will be randomly allocated, using a 2:1 randomization ratio using a permuted 
block randomization on Day 1 to receive treatment with either blinded abaloparatide-SC 80 µg 
per day or daily abaloparatide-SC placebo injections, respectively. Treatment will be blinded to 
subjects, Investigators, and the Sponsor throughout the study unless unblinding is necessary for 
subject treatment in the case of medical emergency, and with exception of Sponsor 
pharmacovigilance and/or regulatory personnel as needed for suspected unexpected serious 
adverse reaction (SUSAR) reporting purposes. All subjects will be provided calcium and vitamin 
D to ensure that their daily intake is in the range of calcium 500–1000 mg/day and vitamin D 
400-800 IU/day, or a dose determined by the Investigator and agreed by the Sponsor Medical 
Monitor, according to the subject’s need. 
Procedures and Assessments 
Refer to the Schedule of Events for full details about the procedures and assessments required at 
each study visit. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 18 of 81 
During the Screening Period, informed consent will be obtained, eligibility for study entry 
assessed, and screening evaluations performed, including baseline lumbar and thoracic spine 
radiographs, BMD assessments by DXA, serum total testosterone, sex hormone binding 
globulin, and baseline laboratory tests. 
• Subjects whose laboratory tests do not fall within the specified ranges as detailed in 
the inclusion/exclusion criteria may have the samples redrawn and the tests repeated 
once during the Screening Period. If upon retesting, the values fall within the 
inclusion/exclusion criteria, the subject may enter the study. 
• Subjects who do not meet the vitamin D entry criterion (their 25-hydroxyvitamin D is 
less than 20 ng/ml) may receive vitamin D supplementation and be retested once 
during the Screening Period as may subjects with minor elevations of PTH. All 
subjects enrolled following retesting must have safety labs within 30 days of 
randomization (Day 1). 
Following these evaluations, eligible subjects will enter the Pretreatment Period of the study and 
will be given daily calcium and vitamin D supplements, which will continue until the end of the 
Treatment Period. Subjects will also receive training in the use of the injector pen for self-
administration. 
At Day 1, the subject will have baseline assessments including bone turnover markers, 
immunogenicity testing, DXA of the wrist, and QCT measurement at the hip (at a subset of 
sites).  
During the Treatment Period, subjects will self-administer a single subcutaneous dose of the 
randomly assigned study medication once a day. Subjects will have clinic visits for study-related 
protocol procedures at Day 1, Month 1, Month 3, Month 6, Month 9, and Month 12. Study 
procedures will include the measurement of BMD by DXA and collection of serum samples to 
assess markers of bone turnover. At each visit, clinical fractures will also be assessed. Serum 
samples for evaluation of calcium after study drug administration and immunogenicity testing 
will be drawn at specified visits during the Treatment Period.  
Statistical Considerations 
The primary population for efficacy analyses will be the Intention-to-Treat (ITT) Population, 
defined as all subjects randomized into this study. The primary population for safety analyses 
will be the Safety Population, defined as all subjects who received at least one dose of study 
medication. The Per-Protocol Population will include all ITT subjects who did not have any 
significant protocol deviations and will be used for supportive analyses. 
Sample Size 
A study sample size of 225 subjects (150 in the abaloparatide-SC group and 75 in the placebo 
group) will provide at least 99% power to detect a mean difference of 6.5% in the percentage 
change from baseline in lumbar spine BMD at 12 months between the abaloparatide-SC and the 
placebo groups at a 2-sided alpha of 0.01, assuming a standard deviation (SD) of 6.0% and a 
drop-out rate of 10%. 
For the key secondary endpoints, this total sample size of 225 subjects will have 96% power to 
detect a 2.2% mean difference (SD = 3.5%) of percent change in total hip BMD at 12 months 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 19 of 81 
and 80% power to detect a 2.0% mean difference (SD = 4.1%) of percent change in femoral neck 
BMD at 12 months. 
Baseline Comparisons 
Baseline characteristics, medical history, physical examination, vital signs, and ECGs will be 
summarized using standard descriptive statistics by treatment group. 
Efficacy Analysis 
The primary and key secondary efficacy endpoints will be analyzed using a fixed-sequence 
testing procedure to control the family-wise error rate for any joint distribution of hypothesis test 
statistics. To claim statistical significance at the 2-sided level of 1%, the following 3 fixed-
sequence tests will be performed in sequential order. At any step of the sequential testing, if the 
treatment difference is not statistically significant at the 1% level then all the subsequent 
comparisons following the fixed sequence cannot be claimed statistically significant. 
1. Percent change from baseline in BMD at the lumbar spine at 12 months 
2. Percent change from baseline in BMD at the total hip at 12 months 
3. Percent change from baseline in BMD at the femoral neck at 12 months 
P-values for treatment comparisons of all other efficacy endpoints will be generated to support 
the study findings without any adjustments for multiplicity. 
For the analysis of BMD data, the primary analysis will be based on a pattern-mixture model 
(PMM) analysis with multiple imputation using the wash-out imputation method. This method 
uses sequential regression and wash-out imputation methodology to impute missing values after 
a subject’s discontinuation from the study. The missing primary endpoint values for subjects in 
the abaloparatide-SC group will be imputed with the observed baseline and data from the 
placebo group; no intermediate values from the abaloparatide-SC group will be used in the 
imputation for the abaloparatide-SC group. For subjects in the placebo group, intermediate 
observed values from the completers in the placebo group will be used while imputing missing 
values during the 12-month Treatment Period. The PROC MI methodology for imputation of 
monotone missing data patterns will be used to impute the outcome variables at consecutive 
visits in a sequential (chain) manner. Each of these imputed datasets will be analyzed using 
analysis of covariance (ANCOVA) with treatment and DXA instrument manufacturer as fixed 
effects and the baseline lumbar spine BMD as a covariate. Results from all imputed datasets will 
be combined using PROC MIANALYZE for overall statistical inference. The statistical tests will 
be 2-sided comparing abaloparatide-SC to placebo; 99% CIs will be presented together with the 
estimated p-values. 
Analysis of bone turnover markers, s-PINP and s-CTX, will be based on the ratio of the post-
baseline value relative to the baseline value at each visit. The transformation of the loge ratio of 
post-baseline versus baseline value will be used to normalize the distributions of the s-PINP and 
s-CTX parameters. The analysis comparing abaloparatide-SC with placebo will use a PMM 
analysis with multiple imputation using the wash-out imputation method, as described for BMD. 
Safety Analysis 
Safety analysis will be analyzed descriptively and will include the following parameters: 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 20 of 81 
• Treatment-emergent AEs (TEAEs) 
• Changes in vital signs (including orthostatic blood pressure [BP]), ECGs, and 
laboratory (hematology, serum chemistry, and urinalysis) tests 
• Investigator and subject assessment of local tolerance 
• Presence of antibodies 
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
Safety 
Recent health status will be obtained, the diary reviewed, and AEs collected at each visit and 
vital signs will be performed at each clinic visit. Laboratory assessments of chemistry and 
hematology, and urinalyses will be obtained at screening, and at Month 1, Month 6, and 
Month 12. A final visit will take place 1 month after the last dose of study medication. 
Any subject who demonstrates decreases in BMD ≥ 7% from baseline of this study at the lumbar 
spine or total hip will have the assessment repeated and, if confirmed, will be notified by the 
Investigator, and be withdrawn from the study. Subjects sustaining a radiologically confirmed 
incident vertebral or nonvertebral fragility fracture will be informed of the finding and will be 
counseled as to treatment options and may discontinue or choose to remain on the study. Should 
a subject who experiences an incident clinical vertebral or nonvertebral fragility fracture choose 
to remain in the study, he will be asked to sign an additional informed consent form explaining 
the potential risks and benefits of remaining in the study. 
Duration of Subject Participation: 
Participation will be up to 16 months (12 months total treatment duration). 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 21 of 81 
1. 
INTRODUCTION 
1.1. 
Background 
Human parathyroid hormone (PTH) is a naturally occurring 84 amino acid hormone and is 
primarily a regulator of calcium homeostasis (Mannstadt et al, 1999). PTH acts directly on bone 
to increase calcium resorption, on the gastrointestinal system to increase calcium absorption, and 
on the kidney to increase calcium reabsorption and 1,25-dihydroxyvitamin D production. In turn, 
PTH levels are tightly regulated by calcium and vitamin D levels. When given intermittently at 
low doses, PTH has a well-documented anabolic effect on bone, and can increase bone mineral 
density (BMD) in a number of intact animal models and in osteoporotic subjects (Dempster et al, 
1993). 
Abaloparatide (marketed as TYMLOS® in the United States [US]) is a novel, synthetic, 34 amino 
acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein 
(PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH[1–34]) and 
76% homology to human PTHrP[1–34]. Abaloparatide is differentiated from PTH and PTHrP 
ligands based on its high affinity and > 1,000-fold greater selectivity for the G protein-coupled 
(RG) vs the non-G protein-coupled (R0) conformation of PTHR1 (Hattersley et al, 2016). 
Differential PTHR1-RG binding with abaloparatide results in potent and transient intracellular 
cyclic adenosine monophosphate (cAMP) signaling. In nonclinical studies, the transient PTHR1 
activation with abaloparatide strongly favors bone anabolism with a limited effect on bone 
resorption (Makino et al, 2015). Thus, abaloparatide was developed with the expectation that it 
would be effective at increasing BMD and reducing fracture in individuals with osteoporosis, but 
with a limited effect on bone resorption and a reduced risk of hypercalcemia. 
1.1.1. 
Disease and Study Drug Background 
Osteoporosis is a systemic skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue that leads to enhanced fragility and increased risk 
of fractures (Rizzoli et al, 2001). This disease is characterized by low BMD and fractures. The 
fractures associated with the greatest morbidity and mortality, as well as economic burden to 
society, together make up the clinically significant and medically relevant group termed major 
osteoporotic fractures. In the US, there are an estimated 2 million osteoporotic fractures annually 
(Litwic et al, 2014). The number of osteoporotic fractures is projected to increase in both men 
and women by more than 3-fold over the next 50 years as a result of the aging population (WHO 
2007). 
Although osteoporosis predominantly affects postmenopausal women, approximately 20% of 
men over the age of 50 years will sustain an osteoporotic-related fracture in their lifetime. In 
2005, the total cost of treatment and rehabilitation for fractures in men in the US was $4.1 billion 
and this is projected to rise to $6.8 billion in 2025 (IOF 2014). Most men experience bone loss 
with aging and low BMD is frequent in older men and a risk factor for fracture. Many different 
risk factors may contribute to bone loss and fracture risk in men, including most importantly 
hypogonadism, glucocorticoids, and excessive alcohol use (Ebeling 2008). Additionally, some 
men develop osteoporosis without apparent cause, so-called idiopathic osteoporosis (Khosla 
2008).  

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 22 of 81 
Bone remodeling occurs through the action of osteoclasts, which are involved in the resorption 
of bone followed by the formation of new bone by osteoblasts. In addition to continued use of 
calcium and vitamin D, the current therapeutic approach to the treatment of osteoporosis through 
inhibition of bone resorption includes agents such as bisphosphonates (Rosen 2005) or 
monoclonal antibody denosumab, that inhibits the action of osteoclasts by binding to receptor 
activator of nuclear factor kappa-B (RANK) ligand. An alternative approach has been to tip the 
balance between osteoblastic bone formation and osteoclastic resorption through the use of 
parathyroid hormone receptor modulation using teriparatide (rhPTH[1–34]). 
Until recently, teriparatide has been the only approved osteoporosis treatment in which the major 
mode of action is stimulation of bone formation (anabolic) rather than suppression of bone 
resorption. The efficacy of teriparatide has important limitations related to its delayed and 
modest effects on increasing BMD at the total hip and femoral neck, and on decreasing BMD at 
the distal one-third radius. The increase in cortical porosity that can occur may result in 
maladaptive effects on cortical bone microarchitecture (Bilezikian 2007). Abaloparatide has been 
evaluated in a number of nonclinical and clinical studies for its potential as a novel treatment for 
osteoporosis. Based on the biology of the PTH1 receptor signaling pathway, abaloparatide is 
designed to have less resorptive and hypercalcemic effects than PTH, resulting in a greater net 
anabolic effect. Abaloparatide has recently been approved in the US for the treatment of women 
with postmenopausal osteoporosis at high fracture risk. In addition to their role in the 
management of postmenopausal osteoporosis, bisphosphonates, denosumab, and teriparatide 
have also been approved for the treatment of osteoporosis in men or to increase bone mass in 
men with osteoporosis. 
1.1.2. 
Study Drug Development 
1.1.2.1. 
Nonclinical Studies in Male Animals 
Abaloparatide was tested in a non-Good Laboratory Practice (GLP) pharmacology study 
(16RADL120) using a male rat castration (orchidectomized [ORX]) model of osteoporosis. Male 
rats underwent ORX or sham surgery at approximately 3 months of age and following a 4-week 
bone depletion period. Treatment was then initiated with either abaloparatide (20 μg/kg/d, n = 8) 
or vehicle (n = 8) once daily for an additional 4-weeks. After 8 weeks of androgen deficiency, 
the ORX group had 13% lower L4 BMD and 17% lower trabecular bone volume fraction (BVF), 
compared with sham controls. After 4 weeks of treatment, the abaloparatide treated group had a 
17% greater L4 BMD, 50% greater BVF, and 33% greater trabecular thickness compared with 
ORX controls (all p < 0.0001), Figure 1. Trabecular bone pattern factor was 39% lower 
compared with ORX controls (p < 0.05), suggesting a more organized and better-connected 
trabecular architecture. The abaloparatide group also had 24% greater BVF and 29% greater 
trabecular thickness, compared with sham controls (both p < 0.01). These data demonstrate that 
abaloparatide reversed vertebral BMD loss and restored trabecular microarchitectural 
deterioration in ORX rats by increasing trabecular bone volume and thickness. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 23 of 81 
Figure 1: 
L4 Vertebral Body BMD after 4 Weeks of Treatment in Male Rats 
 
Two rodent GLP nonclinical studies were completed evaluating abaloparatide effects on male 
reproduction following repeated subcutaneous administration. A 4-week repeat-dose toxicology 
study with male fertility assessment (BA058-114) and a definitive male fertility study with an 
early embryonic development component (SBL062-288) were performed. In both studies, 
Abaloparatide failed to produce adverse effects in male fertility indices, fecundity, early 
embryonic development, and spermatogenesis at exposures up to 128-fold human exposure 
(animal: human exposure multiple) based on a human area under the concentration-time curve 
(AUC) of 1546 pg*hr/mL from Study BA058-05-001B and AUC from the rat 28-day repeat-
dose toxicology Study BA058-114. 
Abaloparatide was tested in repeat-dose toxicity studies in male rats up to 70 μg/kg for up to 
26 weeks (BA058-114, BA058-115 and 7801-124), and in male monkeys at 10 μg/kg for up to 
39 weeks (BA058-119 and 7801-125). The conclusions from the repeat-dose toxicity studies 
were consistent with a primary pharmacology of abaloparatide associated with a new bone 
formation in male animals. There were no significant differences in safety, tolerability or 
histopathological findings between male and female animals noted in these studies. These 
nonclinical results are consistent with abaloparatide having positive bone anabolic effect in male 
animals. 
1.1.2.2. 
Clinical Studies 
There are 19 completed and ongoing clinical studies which comprise the abaloparatide-
subcutaneous (SC) and abaloparatide-solid microstructured transdermal system (sMTS) clinical 
development program. The abaloparatide-SC clinical trial program consists of 11 clinical trials, 
including a large pivotal Phase 3 study (BA058-05-003) followed by an open-label extension 
(Study BA058-05-005) and Phase 2 studies in postmenopausal women with osteoporosis 
(abaloparatide-SC Studies BA058-05-002 and BA058-05-002 extension as well as 
BA058-05-007, an abaloparatide-sMTS study in which abaloparatide-SC at a dose of 80 µg was 
0.44
0.46
0.48
0.5
0.52
0.54
0.56
0.58
SHAM
ORX
ORX + ABL
gHA/cc
Day 28

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 24 of 81 
used as the active comparator) and Phase 1 studies in healthy postmenopausal women, healthy 
male and female subjects, and subjects with renal impairment. 
In the pivotal Phase 3 study (BA058-05-003, the ACTIVE trial), 2,463 postmenopausal women 
were randomized to receive daily 80 µg abaloparatide-SC (n = 824), placebo (n = 821), or 
teriparatide 20 µg (n = 818) (rhPTH 1-34) for 18 months. In this trial, abaloparatide-SC and 
teriparatide significantly reduced the risk of new morphometric vertebral fractures, by 86% and 
80%, respectively, compared to placebo. Abaloparatide-SC significantly reduced nonvertebral, 
major osteoporotic and clinical fractures compared to placebo. Compared to teriparatide, 
abaloparatide significantly reduced major osteoporotic fractures. The Kaplan-Meier plots 
indicate an early and sustained fracture risk reduction of nonvertebral, major osteoporotic and 
clinical fractures with abaloparatide-SC treatment. Abaloparatide-SC has an acceptable safety 
profile, and consistent with reduced abaloparatide-SC-mediated calcium mobilization, the rates 
of hypercalcemia were lower in the abaloparatide-SC group compared to the teriparatide group. 
In the ACTIVExtend trial (BA058-05-005), subjects who were in the abaloparatide-SC or 
placebo arms were transitioned to oral alendronate 70 mg weekly. Subjects who received 
18 months of abaloparatide-SC followed by 6 months of alendronate experienced no new 
morphometric vertebral fractures from Study 005 baseline and continued to have statistically 
significant reductions in nonvertebral, major osteoporotic, and clinical fractures when compared 
to subjects who previously received 18 months of placebo followed by 6 months of alendronate. 
These results validate the osteoporosis treatment paradigm of build (with an anabolic agent), and 
then maintain and consolidate gains (with an antiresorptive agent). 
Abaloparatide-SC demonstrated an increase in BMD at the lumbar spine, total hip, femoral neck, 
and ultra-distal radius in osteoporosis subjects, consistent with the fracture risk reduction. The 
results from the ACTIVE trial and the first 6 months of the ACTIVExtend trial, together with the 
entire data set from the abaloparatide-SC development program, support the safety and efficacy 
of abaloparatide-SC for the reduction of fractures in postmenopausal women with osteoporosis. 
At the 43-month timepoint, the previous abaloparatide-SC treated subjects, who received up to 
2 years of treatment with alendronate, had a significant 84% relative risk reduction (p < 0.0001) in 
the incidence of new vertebral fractures compared with women who received placebo followed by 
alendronate for up to 2 years. They also demonstrated a 39% risk reduction in nonvertebral 
fractures (p = 0.038), a 34% risk reduction in clinical fractures (p = 0.045) and a 50% risk 
reduction in major osteoporotic fractures (p = 0.011) compared with women who received placebo 
followed by alendronate. 
The adverse events (AEs) were comparable between abaloparatide-SC treated subjects and the 
previous placebo group. The incidences of cardiovascular AEs including serious adverse events 
(SAEs) were similar between groups. There have been no cases of osteonecrosis of the jaw (ONJ) 
or atypical femoral fracture (AFF) in the entire abaloparatide-SC development program. 
Overall, the clinical results of abaloparatide-SC-mediated early vertebral and nonvertebral 
fracture risk reduction and increases in BMD are consistent with the known anabolic mechanism 
of action, changes in bone turnover markers and nonclinical results. 
For the most up-to-date information on clinical studies with abaloparatide, refer to the 
abaloparatide Investigator’s Brochure (IB).  

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 25 of 81 
 
1.2. 
Study Rationale 
As noted above, abaloparatide-SC recently became the second bone anabolic agent to be 
approved for the treatment of postmenopausal osteoporosis. While other agents from both 
anabolic and antiresorptive classes of anti-osteoporosis therapies have also been approved for the 
treatment of osteoporosis in men, the safety and efficacy of abaloparatide has yet to be 
demonstrated in osteoporotic men. However, given the existence of an enhanced therapeutic 
response to abaloparatide-SC in postmenopausal women at high risk of fracture, as well as the 
substantive morbidity and mortality burden associated with osteoporotic fractures, confirmation 
of a similarly robust effect of abaloparatide-SC in men is indeed a clinical priority. The present 
study seeks to provide that confirmation, in order for abaloparatide-SC to be made available to 
men with osteoporosis and whose clinical need remains unmet by currently available therapies. 
1.3. 
Dose Rationale 
The approved dose of abaloparatide-SC in the US for the treatment of postmenopausal women at 
a risk for fracture is 80 µg per day, this is also the proposed dose in the European Union (EU). 
While the long-term treatment of men with abaloparatide-SC has not been evaluated, Phase 1 
studies have been conducted to evaluate pharmacokinetics following a single administration of 
abaloparatide-SC, at a dose of 80 µg in both male and female subjects, the proposed dose 
selected for the present study. 
To provide a comparison of pharmacokinetics (PK) and safety for male and female subjects, the 
data from 3 recent Phase 1 clinical trials were pooled (BA058-05-010 was a 
bioavailability/maximum tolerated dose study, BA058-05-011 was a study in subjects with 
varying degrees of renal disease, BA058-05-012 was a study to determine the effects of 
abaloparatide-SC on total depolarization and repolarization time / total depolarization and 
repolarization time corrected with heart rate (QT/QTc) and BA058-05-014 was a study done to 
provide initial evaluation of the bioequivalence of abaloparatide administered subcutaneously 
from 2 similar pen injectors to healthy male and female subjects). Summary PK data are 
presented in Table 1. The 90% CIs for the ratio of AUC and for the ratio of maximum serum 
concentration (Cmax) between males and females were generated based on an analysis of variance 
(ANOVA) model with sex as fixed effect. Maximal time (tmax) values were compared using a t-
test. These results show that there were no differences in the systemic exposure of abaloparatide-
SC between male and female subjects following a single administration of abaloparatide-SC at a 
dose of 80 µg. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 26 of 81 
Table 1: 
Summary of PK Data in Subjects Treated with Abaloparatide-SC 80 µg 
(Pooled Data#) 
Parameters (Unit) 
Statistics 
Female 
Male 
AUClast (pg*h/mL) 
n 
 64 
 92 
Mean (SD) 
664.49 (349.232) 670.41 (345.728) 
Median 
618.50 
567.53 
Q1, Q3 
469.68, 743.95 
390.45, 926.21 
Min, Max 
128.0, 2288.3 
156.9, 1832.0 
MSE 
43.654 
36.045 
Gmean 
591.28 
588.07 
Ratio of Male/Female (90% CI) [1] 
0.9946 (0.8664, 1.1417) 
Ratio of Male/Female (90% CI) [2] 
1.0049 (0.8781, 1.1501) 
AUC0–∞ (pg*h/mL) 
n 
 61 
 88 
Mean (SD) 
703.39 (359.555) 724.75 (363.382) 
Median 
644.00 
618.39 
Q1, Q3 
505.33, 775.74 
428.35, 980.34 
Min, Max 
194.0, 2325.4 
176.2, 1923.0 
MSE 
46.036 
38.737 
Gmean 
632.53 
641.28 
Ratio of Male/Female (90% CI) [1] 
1.0138 (0.8861, 1.1600) 
Ratio of Male/Female (90% CI) [2] 
1.0323 (0.9056, 1.1768) 
Cmax (pg/mL) 
n 
 64 
 92 
Mean (SD) 
524.69 (168.997) 467.17 (152.786) 
Median 
507.00 
455.00 
Q1, Q3 
416.00, 618.00 
366.00, 545.00 
Min, Max 
198.0, 1140.0 
214.0, 928.0 
MSE 
21.125 
15.929 
Gmean 
498.86 
443.77 
Ratio of Male/Female (90% CI) [1] 
0.8896 (0.8153, 0.9706) 
Ratio of Male/Female (90% CI) [2] 
0.8943 (0.8195, 0.9758) 
tmax (h) 
n 
 64 
 92 
Mean (SD) 
0.40 (0.191) 
0.42 (0.177) 
Median 
0.33 
0.33 
Q1, Q3 
0.25, 0.50 
0.25, 0.50 
Min, Max 
0.3, 1.1 
0.3, 1.1 
MSE 
0.024 
0.018 
Gmean 
0.36 
0.39 
P-value [3] 
0.4177 
t½ (h) 
n 
 62 
 89 
Mean (SD) 
1.26 (2.270) 
1.07 (0.565) 
Median 
0.96 
0.95 
Q1, Q3 
0.77, 1.11 
0.67, 1.30 
Min, Max 
0.5, 18.7 
0.4, 3.2 
MSE 
0.288 
0.060 
Gmean 
0.97 
0.96 
# The data include studies BA058-05-010, BA058-05-011, BA058-05-012, and BA058-05-014. Ten female subjects 
and 17 male subjects in Study BA058-05-014 received 2 doses of abaloparatide-SC; both PK profiles are included in 
the summary table. 
[1] Ratio is based on ANOVA model with sex as fixed effect. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 27 of 81 
[2] Ratio is based on ANOVA model with sex and study as fixed effects. 
[3] P-value is based on T-test 
AUC0–∞ = area under the plasma concentration-time curve from time zero to infinity; AUClast = area under the plasma 
concentration-time curve from time zero to the time of the last quantifiable concentration; Cmax = maximum plasma 
concentration; Gmean = geometric mean; MSE = standard error of the mean;.Q1, Q3 = interquartile range; SD = 
standard deviation; t1/2 = apparent terminal phase half-life; tmax = time to reach maximum plasma concentration 
following drug administration. 
Postdose BQL values were set to half the LLOQ for computation of mean postdose concentration values. 
 
There were also no apparent differences in abaloparatide clearance (Figure 2). 
 
Figure 2: 
PK Concentration over Time in Subjects Treated with Abaloparatide-SC 
80 µg (Pooled Data#) 
 
# The data include studies BA058-05-010, BA058-05-011, BA058-05-012, and BA058-05-014. 
Abaloparatide Concentration Mean (+/- SE) (pg/mL)
0
50
100
150
200
250
300
350
400
450
500
550
Time Point (Hour)
0
1
2
3
4
5
6
7
8
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Female
Male

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 28 of 81 
Figure 3: 
Study BA058-05-012 – Mean (95% CI) Change from Baseline in Serum 
Calcium over Time by Gender for Abaloparatide 80 µg Treatment (Safety 
Population) 
 
In the clinical trial of women with postmenopausal osteoporosis (BA058-05-003), 
abaloparatide-SC caused increases in serum calcium concentrations, evident at 4-hours post 
administration. Serum calcium concentrations were assessed in both male and female subjects in 
Study BA058-05-012. In this study, male and female subjects were dosed with a single injection 
of 80 µg of abaloparatide-SC. Serum calcium levels were measured at baseline, and at 2, 4, and 
8 hours postdose. Although the levels across time were slightly higher in males than in females 
(Figure 3), the temporal pattern of change in serum calcium concentration was similar, with the 
maximal concentrations observed approximately 4 hours after dosing. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 29 of 81 
Table 2: 
Pooled Treatment-Emergent Adverse Events – Differences Between Male 
and Female Subjects in Phase 1 Studies (BA05805-010, BA05805-010, 
BA05805-011, BA05805-012, and BA05805-014) * 
System Organ Class 
  Preferred Term 
Female 
(N = 54) 
n (%) 
Male 
(N = 77) 
n (%) 
At Least one TEAE 
25 (46.3) 
16 (20.8) 
 
Cardiac disorders 
2 (3.7) 
1 (1.3) 
  Bundle branch block left 
1 (1.9) 
0 
  Palpitations 
1 (1.9) 
0 
  Postural orthostatic tachycardia syndrome 
0 
1 (1.3) 
 
Gastrointestinal disorders 
4 (7.4) 
4 (5.2) 
  Nausea 
3 (5.6) 
4 (5.2) 
  Abdominal distension 
1 (1.9) 
0 
  Abdominal pain 
1 (1.9) 
0 
  Diarrhoea 
1 (1.9) 
0 
  Vomiting 
0 
1 (1.3) 
 
General disorders and administration site conditions 
9 (16.7) 
4 (5.2) 
  Injection site erythema 
8 (14.8) 
3 (3.9) 
  Injection site pruritus 
5 (9.3) 
0 
  Application site erythema 
1 (1.9) 
0 
  Chills 
0 
1 (1.3) 
  Injection site haemorrhage 
0 
1 (1.3) 
 
Infections and infestations 
1 (1.9) 
0 
  Viral upper respiratory tract infection 
1 (1.9) 
0 
 
Investigations 
1 (1.9) 
0 
  Blood pressure increased 
1 (1.9) 
0 
 
Metabolism and nutrition disorders 
1 (1.9) 
1 (1.3) 
  Decreased appetite 
1 (1.9) 
1 (1.3) 
 
Musculoskeletal and connective tissue disorders 
1 (1.9) 
1 (1.3) 
  Musculoskeletal pain 
1 (1.9) 
0 
  Myalgia 
0 
1 (1.3) 
 
 
 
Nervous system disorders 
13 (24.1) 
10 (13.0) 
  Headache 
11 (20.4) 
7 (9.1) 
  Dizziness postural 
2 (3.7) 
2 (2.6) 
  Dizziness 
1 (1.9) 
2 (2.6) 
  Paraesthesia 
0 
1 (1.3) 
  Somnolence 
0 
1 (1.3) 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 30 of 81 
System Organ Class 
  Preferred Term 
Female 
(N = 54) 
n (%) 
Male 
(N = 77) 
n (%) 
Respiratory, thoracic and mediastinal disorders 
2 (3.7) 
1 (1.3) 
  Dyspnoea 
1 (1.9) 
0 
  Oropharyngeal pain 
1 (1.9) 
0 
  Nasal congestion 
0 
1 (1.3) 
  Productive cough 
0 
1 (1.3) 
 
 
 
Skin and subcutaneous tissue disorders 
1 (1.9) 
0 
  Erythema 
1 (1.9) 
0 
 
 
 
Vascular disorders 
1 (1.9) 
0 
  Orthostatic hypotension 
1 (1.9) 
0 
Each subject was counted once for the same system organ class and the same preferred term. 
Preferred terms were sorted by descending order of counts by female and male. 
TEAE = treatment-emergent adverse event 
 
Abaloparatide has been studied in the male population, and differences in treatment-emergent 
adverse events (TEAEs) were observed between males and females (Table 2). In pooled data 
across 4 Phase 1 studies (BA05805- 010, BA05805-011, BA05805-012, and BA05805-014), 25 
of 54 females (46.3%) and 16 of 77 males (20.8%) experienced at least one TEAE. 
Based on these results, which demonstrated no apparent difference in the systemic exposure of 
abaloparatide-SC between males and females across 4 different Phase 1 clinical trials, together 
with Phase 3 safety and efficacy data showing significant increases in BMD in osteoporotic 
women following 6, 12, and 18 months of treatment with abaloparatide-SC, the 80-µg dose is 
therefore an appropriate dose for the treatment of men with osteoporosis. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 31 of 81 
2. 
STUDY OBJECTIVES AND ENDPOINTS 
2.1. 
Primary Objective and Endpoint 
The primary objective of this prospective controlled study is to evaluate the efficacy and the 
safety of abaloparatide-SC 80 µg per day compared to placebo in men with osteoporosis. The 
primary efficacy endpoint is the percent change from baseline in lumbar spine BMD at 
12 months. 
2.2. 
Secondary Endpoints 
The key secondary efficacy endpoints are: 
• Percent change from baseline in total hip BMD at 12 months 
• Percent change from baseline in femoral neck BMD at 12 months 
Additional secondary efficacy endpoints are: 
• Percent change in baseline in: 
− Lumbar spine BMD at 3 and 6 months 
− Total hip BMD at 3 and 6 months  
− Femoral neck BMD at 3 and 6 months 
− Ultra-distal radius BMD at 3, 6, and 12 months 
− Distal one-third radius BMD at 3, 6, and 12 months 
• Log ratio of post-baseline over baseline in: 
− Serum procollagen type I N-terminal propeptide (s-PINP) at 1, 3, 6, and 
12 months 
− Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTX) at 1, 
3, 6, and 12 months 
• Proportion of subjects experiencing BMD gains from baseline of > 0%, > 3%, and 
> 6% at the lumbar spine, femoral neck, and total hip at 3, 6, and 12 months 
• Incidence of new clinical fractures at 12 months 
• Proportion of subjects converting from the categories of osteoporosis to osteopenia or 
to normal at 12 months, where: 
− Osteoporosis is defined as lumbar spine or total hip BMD T-score ≤ -2.5.  
− Osteopenia is defined as as one of the following: 
o Lumbar spine > -2.5 and total hip BMD T-score > -2.5 and < -1.0  
o Lumbar spine > -2.5 and < -1.0 and total hip BMD T-score > -2.5  
− Normal is defined as lumbar spine and total hip BMD T-score ≥ -1.0.  

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 32 of 81 
• The percent change in total hip and femoral neck volumetric BMD as measured by 
quantitative CT (QCT) from baseline to 12 months QCT will be performed in a subset 
of subjects in a selected number of study sites. 
For those subjects who consent to PK sample collection, the PK endpoints are: 
• The plasma concentration of abaloparatide based on sparse PK sampling at the 
following visits: 
− Month 6: postdose PK samples collected 45 minutes (±15 minutes) and 2.5 hours 
(±0.5 hour) after abaloparatide-SC injection 
− Month 9: postdose PK samples collected 20 minutes (±10 minutes) and 4 hours 
(±0.5 hour) after abaloparatide-SC injection 
− Month 12: a predose sample and a postdose sample collected 1.5 hours 
(±0.5 hour) after abaloparatide-SC injection 
The safety endpoints are: 
• Overall safety and tolerability of abaloparatide-SC in men with osteoporosis as 
assessed by AEs, vital signs, electrocardiograms (ECGs), laboratory tests of 
chemistry and hematology, urinalysis, local tolerance, and presence of antibodies 
Subgroup analysis (e.g., age, geography, FRAX (if applicable), prior fracture, and baseline 
BMD, s-PINP, testosterone and estradiol levels) may be performed and will be described in the 
Statistical Analysis Plan (SAP). 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 33 of 81 
3. 
STUDY DESIGN 
3.1. 
Description of the Study Design 
This is a randomized, double-blind, placebo-controlled, Phase 3, multicenter study enrolling 
approximately 225 subjects at approximately 40 study sites designed to evaluate the efficacy and 
safety of abaloparatide-SC 80 µg per day for the treatment of osteoporosis in men. The study will 
consist of a Screening Period (up to 2 months), a Pretreatment Period (1 week), and a Treatment 
Period (12 months) with a Follow-up Visit 1 month after the last dose of study medication.  
During the Screening Period, informed consent will be obtained, eligibility for study entry 
assessed, and screening evaluations performed. Subjects who are eligible for the study, on the 
basis of screening evaluations, will enter the Pretreatment Period of the study and will have 
additional baseline assessments.  
Subjects who remain eligible for study participation will be randomly allocated, using a 
2:1 randomization ratio on Day 1 to receive treatment with either blinded abaloparatide-SC 
80 µg per day or daily placebo injections, respectively. Treatment will be blinded to subjects and 
Investigators throughout the study except in a medical emergency where the identity of study 
medication is necessary to appropriately treat the subject (Section 5.7). The Sponsor 
pharmacovigilance/regulatory personnel may also be unblinded for suspected unexpected serious 
adverse reaction (SUSAR) reporting purposes.  
All subjects will receive calcium 500–1000 mg/day and vitamin D 400–800 IU/day, or a dose 
determined by the Investigator and agreed by the Sponsor Medical Monitor, according to the 
subject’s need. 
The study design is presented in Figure 4, below. All subjects will undergo safety, BMD, bone 
marker, and fracture assessments at regular intervals, according to the Schedule of Assessments 
and Procedures (Table 3). Subjects will be asked if they are willing to provide PK samples to 
evaluate the amount of abaloparatide in the plasma at various timepoints. Those subjects who 
consent to this sparse PK sampling will have samples collected at Months 6, 9, and 12 as shown 
in Table 4. 
Figure 4: 
Study BA058-05-019 Design 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 34 of 81 
4. 
SELECTION OF STUDY POPULATION 
To participate in this study, a subject must meet all of the inclusion criteria listed in Section 4.1 
and none of the exclusion criteria listed in Section 4.2. Subjects who were screened and excluded 
from this study will be recorded in the electronic case report form (eCRF), as well as the reason 
why they were screen failures. 
4.1. 
Inclusion Criteria 
1. The subject is a healthy ambulatory male from 40 to 85 years of age (inclusive) with 
primary osteoporosis or osteoporosis associated with hypogonadism. 
2. The subject has a BMD T-score (based on the male reference range as assessed by the 
central imaging vendor) of: 
a. ≤ -2.5 at the lumbar spine (L1–L4) or hip (femoral neck or total hip) by dual energy 
X-ray absorptiometry (DXA); or 
b. ≤ -1.5 and with radiologic evidence of vertebral fracture or a documented history of 
low-trauma nonvertebral fracture sustained in the past 5 years.  
c. Men older than 65 years may be enrolled if they have a BMD T-score ≤ -2.0 even if 
they do not meet the fracture criteria. 
3. The subject is in good general health as determined by medical history and physical 
examination (including vital signs) and is without evidence of a clinically significant 
abnormality in the opinion of the Investigator, or none for which there is a reasonable 
chance of interfering with the subject’s health and/or medical treatment during the study. 
The subject has a body mass index (BMI) of 18.5 to 33, inclusive. The BMI is derived 
from the subject’s height and weight. In the case where a subject’s height cannot be 
adequately assessed (e.g., due to vertebral compression fractures or scoliosis), the subject’s 
historical height (as documented in the subject’s medical record) will be used to derive the 
BMI. 
4. Hypogonadal subjects whose doses of androgens have been stable for at least 12 months 
before randomization are eligible and may continue therapy during the study. 
5. The subject has serum calcium (albumin-corrected), PTH, serum phosphorus and alkaline 
phosphatase, and thyroid stimulating hormone (TSH) values all within the normal range 
during the Screening Period. Any subject with an elevated alkaline phosphatase value and 
who meets all other entry criteria must have a normal bone-specific alkaline phosphatase 
to be enrolled. Any subject with a TSH value outside of the normal range must have 
central laboratory reported T3 and free T4 values within the normal ranges to be enrolled. 
6. The subject has serum 25-hydroxyvitamin D values ≥ 20 ng/mL and within normal range. 
Subjects with serum 25-hydroxyvitamin D levels < 20 ng/ml may be treated with vitamin 
D and retested once during the Screening Period. 
7. The subject’s systolic blood pressure is ≥ 100 and ≤ 155 mmHg, diastolic blood pressure 
is ≥ 40 and ≤ 95 mmHg, and heart rate is ≥ 45 and ≤ 100 bpm (taken sitting or supine). 
Any recorded values outside of these ranges and assessed by the Investigator to be not 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 35 of 81 
clinically significant must be reviewed with the Sponsor Medical Monitor for approval 
prior to enrollment. 
8. The subject has no clinically significant abnormality of serum hemoglobin, hematocrit, 
white blood cells, and platelets, or usual serum biochemistry: electrolytes, renal function, 
liver function and serum proteins that might be expected to interfere with the subject’s 
health and/or medical treatment during the study. 
9. In subjects who have partners of childbearing potential, the subject and his partner should 
abstain from sexual intercourse, or use highly effective contraceptive measures (e.g., oral 
contraceptive and condom, intrauterine device [IUD] and condom, or diaphragm with 
spermicide and condoms; other forms of contraception must be approved by the Medical 
Monitor) when engaging in sexual intercourse throughout the study, and for at least 90 
days after the last dose of abaloparatide.  
10. The subject has read, understood, and signed the written informed consent form (ICF). 
4.2. 
Exclusion Criteria 
General exclusion criteria: 
1. Presence of abnormalities of the lumbar spine that would prohibit assessment of spinal 
BMD, defined as having at least 2 radiologically evaluable vertebrae within L1–L4 as 
assessed by the central imaging vendor. 
Anatomically abnormal vertebrae are excluded if: 
• They are clearly abnormal and non-assessable within the resolution of the system; or 
• There is a more than 1.0 T-score difference between the vertebra in question and 
adjacent vertebrae. 
2. A BMD T-score of ≤ -3.5 at the total hip, femoral neck, or lumbar spine based upon the 
male reference range. 
3. Unevaluable hip BMD or subjects who have undergone bilateral hip replacement 
(unilateral hip replacement is acceptable). 
4. Fragility fracture within the prior 12 months. 
5. History of severe vertebral fracture or > 2 moderate vertebral fractures. 
6. History of bone disorders (e.g., Paget’s disease) other than osteoporosis. 
7. Subjects with clinical signs of hypogonadism present at screening who plan to initiate 
testosterone replacement. 
8. History of prior external beam or implant radiation therapy involving the skeleton, other 
than radioiodine. 
9. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, 
gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or 
immunologic, emotional and/or psychiatric disturbances to a degree that would interfere 
with the interpretation of study data or compromise the safety of the subject. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 36 of 81 
10. History of Cushing’s disease, growth hormone deficiency or excess, hyperthyroidism, 
hypo- or hyperparathyroidism or malabsorptive syndromes within the past year. 
11. History of significantly impaired renal function (serum creatinine > 177 μmol/L or 
> 2.0 mg/dL). If the serum creatinine is > 1.5 and ≤ 2.0 mg/dL, the calculated creatinine 
clearance (Cockcroft-Gault) must be ≥ 37 mL/min. 
12. History of any cancer within the past 5 years (other than basal cell or squamous cancer of 
the skin). 
13. History of osteosarcoma at any time. 
14. Subjects with hereditary disorders predisposing them to osteosarcoma. 
15. History of nephrolithiasis or urolithiasis within the past 5 years. 
16. Subjects known to be positive for Hepatitis B, Hepatitis C, human immunodeficiency 
virus (HIV)-1 or HIV-2. Testing is not required in the absence of clinical signs and 
symptoms suggestive of HIV infection or acute or chronic hepatitis. 
Medication-related exclusion criteria: 
17. Known history of hypersensitivity to any of the test materials or related compounds. 
18. Prior treatment with PTH- or PTHrP-derived drugs, or bone anabolic drugs including 
abaloparatide or teriparatide, or PTH(1-84). 
19. Prior treatment with intravenous (IV) bisphosphonates at any time or oral 
bisphosphonates within the past 3 years. Subjects who had received a short course of oral 
bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment 
occurred 6 or more months prior to enrollment. 
20. Treatment with fluoride or strontium in the past 5 years or prior treatment with gallium 
nitrate or other bone-acting investigational agents at any time. Limited use of gallium 
citrate/nitrate for diagnostic purposes (i.e., a gallium scan) is not exclusionary.  
21. Prior treatment with calcitonin or tibolone in the past 6 months. 
22. Prior treatment with denosumab in the past 18 months. 
23. Treatment with anticonvulsants that affect vitamin D metabolism (phenobarbital, 
phenytoin, carbamazepine, or primidone) or with chronic heparin within the 6 months 
prior to the Screening Period. 
24. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) 
within the past 90 days 
25. Daily treatment with oral, intranasal, or inhaled corticosteroids within the 12 months 
prior to the Screening Period. Occasional use of all corticosteroids (for seasonal allergies 
or asthma) is not exclusionary. 
26. Exposure to an investigational drug within the 12 months prior to the Screening Period. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 37 of 81 
Lifestyle-related exclusion criteria: 
27. Abnormal nutritional status (as assessed by the Investigator), vitamin D intake of 
≥ 4,000 IU/day or vitamin A intake of ≥ 10,000 IU/day. Short term use of high doses of 
vitamin D to increase endogenous vitamin D levels for study entry is not exclusionary. 
28. Subject is known to consume > 2 alcoholic drinks per day, to use illegal drugs, or to 
abuse tobacco or marijuana (medicinally or recreationally where legal) within 12 months 
of the Screening Period. The Investigator must determine and document use vs. abuse of 
tobacco or marijuana. 
4.3. 
Participant Withdrawal or Termination 
4.3.1. 
Reasons for Withdrawal or Termination 
Subjects will be informed that they have the right to withdraw from the study at any time for any 
reason without prejudice to their medical care. 
The Investigator must withdraw subjects from the study for the following reasons: 
• Continuing significant deterioration from baseline (≥ 7%) of BMD at spine or hip 
(after confirmation of the finding) 
• Hypercalcemia as described in Section 4.7.1 
• Severe hypersensitivity to abaloparatide 
• Refusal of treatment 
• Inability to complete study procedures 
• Lost to follow-up 
The Investigator also has the right to withdraw subjects from the study for any of the following 
reasons: 
• Serious AEs (as described in Section 7.1.3) 
• A complex of AEs which, in the judgment of the Investigator justifies treatment 
cessation 
• Serious intercurrent illness 
• Noncompliance 
• Protocol deviations 
• Administrative reasons 
Subjects will be offered the opportunity to discontinue from the study for the following reasons 
after site consultation with the Study Medical Monitor: 
• Incident vertebral or nonvertebral fragility fracture 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 38 of 81 
Should a subject who experiences a clinical vertebral or nonvertebral fragility fracture choose to 
remain in the study, they will be asked to sign an additional ICF further explaining the potential 
risks and benefits of remaining in the study. 
If a subject withdraws from the study due to the ongoing coronavirus disease 2019 (COVID-19) 
global pandemic, this information will be captured in the eCRF so that it can be described in the 
clinical study report at the end of the study, in line with the Food and Drug Administration 
(FDA) Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public 
Health Emergency (FDA 2021).  
The reason for the withdrawal should be recorded in the eCRF as COVID-19, if applicable, and 
include as many details as possible (e.g., the subject had a positive test result or decided to 
withdraw from the study due to personal choice related to COVID-19 concerns). 
4.3.2. 
Handling of Participant Withdrawals or Terminations 
If a subject is withdrawn or discontinued from the study, the reason for withdrawal from the 
study is to be recorded in the source documents and on the CRF. All subjects withdrawn prior to 
completing the study should be encouraged to complete study procedures scheduled for the 
Month 12/Early Termination visit as soon as possible, and to return in 1 month for a Follow-up 
Visit. All AEs should be followed as described in Section 7. Subjects who discontinue or are 
withdrawn from the study will not be replaced. 
4.4. 
Concomitant Medications 
Calcium (500–1000 mg/day) and vitamin D (400–800 IU/day) supplements, or a dose 
determined by the Investigator and approved by the Sponsor Medical Monitor, according to the 
subject’s need, are required to be administered daily from the Pretreatment Period until the end 
of the Treatment Period. The doses and schedule of calcium and vitamin D supplements, which 
are part of the study medication protocol, should be adhered to and not be changed other than for 
medical necessity. The supplements should be taken in the evening with or without food or as 
otherwise instructed by the Investigator. 
For any required concomitant chronic medication, such as statins or antihypertensives, the 
subject must be on a stable dose for 90 days prior to study entry and every effort should be made 
to maintain a stable dose during study participation. If a medication or dose has not been 
consistent for 90 days prior to study entry, recent changes must have been due to reasons other 
than lack of control of the underlying medical condition, i.e., the underlying medical condition 
for which chronic medication is required must be well-controlled.  
The occasional use of over-the-counter medications at labeled doses (e.g., ibuprofen or 
acetaminophen) for headache or minor discomfort is allowed. These are to be recorded in the 
source records and entered in the appropriate CRF. Subjects should not take any other 
medications, including over-the-counter medications, herbal medications, or mega-doses of 
vitamins during the study without prior approval of the Investigator. 
If it becomes necessary for a subject to take any other medication during the study, the specific 
medication(s) and indication(s) must be discussed with the Investigator. All concomitant 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 39 of 81 
medications taken during the course of the study must be recorded in the subject’s medical 
record or source document and transcribed into the eCRF. 
4.5. 
Prohibited Medications 
Please refer to Section 4.2 for medication-related exclusion criteria. 
Subjects cannot take any medications, including over-the-counter, non-prescription medication, 
with the exception of those noted in Section 4.4, within 72 hours prior to dosing on Day 1. 
In addition, subjects are ineligible for the study if they have an abnormal nutritional status 
(abnormal diets, excessive or unusual vitamin or herbal intakes, malabsorption). 
Occasional short term (≤ 3 months) use of corticosteroids for seasonal allergies or asthma is not 
prohibited. Subjects who require chronic treatment with either an anticonvulsant (phenobarbital, 
phenytoin, carbamazepine, or primidone), or with heparin will be discontinued. 
4.6. 
Premature Termination or Suspension of Study 
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification documenting the reason for study suspension or 
termination will be provided by the suspending or terminating party to the principal investigator 
(PI), and regulatory authorities. If the study is prematurely terminated or suspended, the PI will 
promptly inform the Institutional Review Board (IRB) / Independent Ethics Committee (IEC) 
and will provide the reason(s) for the termination or suspension. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
• Determination of unexpected, significant, or unacceptable risk to participants. 
• Insufficient compliance with protocol requirements. 
• Data that are not sufficiently complete and/or evaluable. 
• Decision of Sponsor. 
Study may resume once concerns about safety, protocol compliance, or data quality are 
addressed and satisfy the Sponsor, IRB/IEC, and/or regulatory agencies, if applicable. 
4.7. 
Temporary Suspension of Treatment 
The Investigator has the right to suspend treatment with study medication for up to 
14 continuous days or 28 cumulative days, without withdrawal of the subject from the study. 
Reasons for temporary suspension of treatment may include a medical reason unrelated to an 
adverse event (e.g., a planned procedure), or important social or administrative events. The 
reason for the suspension of treatment is to be documented in the CRF and in source documents. 
Such subjects should not be unblinded as to study medication. 
When treatment is restarted, the subject should resume treatment with the next scheduled dose 
and continue until the scheduled End-of-Treatment. If the treatment suspension is due to a 
medical emergency and study medication needs to be unblinded, please refer to Section 5.7 for 
the procedures to be followed. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 40 of 81 
 Subjects who develop hypercalcemia or hypercalciuria during the study are to have treatment 
with calcium and vitamin D temporarily suspended as described below. 
4.7.1. 
Treatment Algorithm in Subjects Who Develop Hypercalcemia 
Hypercalcemia is defined as any serum calcium (albumin-corrected) that is ≥ 0.3 mg/dL 
(equivalent to > 0.08 mmol/L) above the upper limit of normal (ULN). For this study, the normal 
range, ULN and lower limit of normal (LLN) for serum calcium (albumin-corrected) are 
determined by the central laboratory. 
For any predose serum calcium (albumin-corrected) value which is ≥ 0.3 to 1.0 mg/dL, 
corresponding to ≥ 0.08 to 0.25 mmol/L, above the ULN (inclusive), confirm hypercalcemia by 
drawing a new serum sample as soon as possible after the result is received (Figure 5). 
• If the repeat serum calcium (albumin-corrected) is above the LLN up to < 0.3 mg/dL 
(equivalent to < 0.08 mmol/L) above the ULN, the subject should continue study drug 
administration together with Calcium and vitamin D supplementation. 
• If a subject’s predose serum calcium is elevated on repeat testing, calcium and 
vitamin D supplementation should be withheld. The subject is to continue study drug 
administration during this interval. 
• If the subject’s predose serum calcium remains elevated 1-2 weeks after calcium and 
vitamin D supplementation is withheld, dosing of study drug should be stopped.  
Treatment can be restarted if other causes of hypercalcemia are excluded after consultation with 
the Sponsor. Treatment with study drug should not be suspended for greater than 14 days. 
If the subject continues in the study (with calcium and vitamin D supplements) and had an 
episode of a predose serum calcium (albumin-corrected) value of ≥ 0.3 to 1.0 mg/dL 
(corresponding to ≥ 0.08 to 0.25 mmol/L) above the ULN, repeat testing of the predose serum 
calcium (albumin-corrected). 
• If the subject’s serum calcium (albumin-corrected) value again returns to normal 
when not taking calcium and vitamin D supplements, the subject may continue in the 
study without calcium and vitamin D supplements. 
• If the retest is still elevated, contact the Sponsor Medical Monitor to assess whether 
the subject is to be discontinued from the study. 
For any serum calcium (albumin-corrected) value > 1.0 mg/dL above the ULN: 
• Discontinue calcium and vitamin D supplements and discontinue the study drug as 
soon as the result is received. Confirm hypercalcemia by drawing a new serum 
sample as soon as possible. 
• If the result of the retest remains > 1.0 mg/dL above the ULN, perform a second retest 
after 3 days without calcium and vitamin D supplements and study drug. 
− If the second retest is normal, the subject may continue in the study and resume 
study drug including the calcium and vitamin D supplements. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 41 of 81 
− If the second retest is still elevated, contact the Sponsor Medical Monitor to assess 
whether the subject is to be discontinued from the study. 
• If the subject continues in the study and has a repeat episode of serum calcium 
> 1.0 mg/dL above the ULN, contact the Sponsor Medical Monitor to assess whether 
the subject is to be discontinued from the study. 
4.7.2. 
Treatment Algorithm in Subjects Who Develop Hypercalciuria 
For a urine calcium:creatinine ratio > 0.4 mg/mg, corresponding to > 1.131 mmol/mmol, check 
the subject’s predose serum calcium and apply the algorithm outlined in Section 4.7.1 if calcium 
is elevated. 
If the calcium:creatinine ratio is > 0.4 mg/mg and the serum calcium is normal: 
• Discontinue calcium and vitamin D supplements and recheck urine calcium:creatinine 
values after 7 days. 
− If the urine calcium:creatinine ratio continues to be > 0.4 mg/mg in the presence 
of normal serum calcium, the subject may continue in the study under medical 
supervision (and without receiving additional calcium and vitamin D 
supplements). 
− If the urine calcium:creatinine ratio returns to normal, the subject may restart 
calcium and vitamin D supplements and continue in the study. 
• If the subject restarts the serum calcium and vitamin D supplements and 
hypercalciuria returns, calcium and vitamin D supplementation should be terminated. 
The subject may continue in the study under medical supervision. 
Therefore, subjects with hypercalciuria will not be discontinued from the study in the absence of 
hypercalcemia except at the discretion of the Investigator. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
 
Study BA058-05-019 Amendment 6 
 
 
 
 
 
Page 42 of 81 
 
Figure 5: 
Treatment Algorithm in Subjects Who Develop Hypercalcemia 
 
*For any predose serum calcium (albumin-corrected) > 1.0 mg/dL (> 0.25 mmol/L) above the upper limit of normal (ULN), immediately discontinue calcium, vitamin D, 
and study drug 
**ULN, lower limit of normal, and normal ranges are determined per the central laboratory 
*** If applicable, also consider restarting/continuing vitamin D and calcium supplementation after consultation with the Sponsor 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
 
Study BA058-05-019 Amendment 6 
 
Page 43 of 81 
5. 
STUDY DRUG ADMINISTRATION AND MANAGEMENT 
5.1. 
Study Medication 
5.1.1. 
Abaloparatide-SC and Placebo 
Abaloparatide-SC injection is supplied as a sterile, colorless, clear solution in a glass 
cartridge which is pre-assembled into a disposable single-subject-use pen. The pen is 
intended to deliver 30 once daily abaloparatide doses of 80 µg in 40 µL of solution. Each pen 
contains 3120 μg/1.56 mL.  
Placebo is formulated similarly but without active abaloparatide and will be similarly 
supplied as a sterile, colorless, clear solution in a glass cartridge which is pre-assembled into 
a disposable single-subject-use pen. The pen is intended to deliver 30 once daily placebo 
doses of 80 µg in 40 µL of fluid when inserted into the Pen Injector device. 
Additional information will be provided to clinical sites in a separate Pharmacy Manual 
including instructions on how to use the injection pen. 
5.1.2. 
Calcium and Vitamin D Supplements 
Calcium (500–1000 mg) and vitamin D (400–800 IU) supplements will be sourced locally by 
the site and provided to subjects at the expense of the Sponsor. 
5.2. 
Packaging, Labeling and Storage 
5.2.1. 
Packaging and Labeling 
Abaloparatide-SC and placebo will be supplied and packaged as identical injection pens. All 
packaging operations will be performed in accordance with Good Manufacturing Practices 
(GMP). 
Study medication will be provided and replaced via the interactive response technology (IRT) 
on clinic visit days. If clinic visits are not possible, study medication may also be delivered to 
the subject’s home. Labeling will include a caution statement and other information required 
by local regulatory authorities. A detailed study drug dispensation plan will be provided in 
the Pharmacy Manual. 
Calcium and vitamin D supplements will be provided as packaged by the manufacturer and 
will not be relabeled for the study. 
5.2.2. 
Storage 
While at the clinical site, abaloparatide and placebo injection pens must be stored in a secure, 
limited access, temperature monitored refrigerator at 2° to 8°C (36° to 46°F) until dispensed 
for use to a study subject or until returned to the Sponsor. 
After the abaloparatide-SC or placebo injection pen is used for the first time, the pen may be 
stored for 30 days at room temperature, 68°F to 77°F (20°C to 25°C). Unused pens should be 
refrigerated until initial use. Instructions regarding the storage and handling of the study drug 
after dispensation to subjects will be provided to sites in the Pharmacy Manual. 
Calcium and vitamin D supplements should be stored according to the manufacturer 
recommendations on the bottle. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 44 of 81 
5.3. 
Treatment Assignment 
All subjects who sign informed consent for the study will be assigned a unique 6-digit subject 
number which will be used to identify subjects throughout the study and in the eCRFs. 
 
 
 
 
 
 
Subjects who meet all inclusion criteria and none of the exclusion criteria and successfully 
complete the Screening and Pretreatment Periods of the study will be assigned sequentially to 
a randomized treatment group on Day 1 of the Treatment Period. Subjects will only receive 
one study ID at the time of screening and therefore will not receive a new identifier at 
randomization. During the randomization transaction, the IRT will randomly allocate a 
treatment assignment and dispense the appropriate kit number for the subject’s treatment. 
Information regarding treatment assignment will reside solely within the IRT, as part of the 
study blinding. Once a kit number has been assigned, it may not be reused. Refer to the IRT 
manual for additional details on IRT instructions. 
Prior to study start, the Sponsor statistician will be responsible for overseeing the preparation 
of the master randomization scheme that will be used to package study medication into kits 
and for the IRT. 
5.4. 
Dosing and Administration 
Subjects will self-administer a single daily dose of 80 µg of study medication during the 
Treatment Period. 
The first self-administration is to occur at the study site under observation. On the days of 
clinic visits, study medication must be administered in the clinic to accommodate pre-
injection and post-injection procedures; study personnel may administer the study 
medication. For the Month 12 visit, subjects should be instructed to bring the study drug 
dispensed at the last study visit and to administer the study drug onsite. 
Subjects will be trained by study personnel during the Pretreatment Period how to self-inject 
study medication with the abaloparatide-SC/Placebo injection pen. If a subject requires 
assistance with study medication administration, an individual (e.g., a family member) who 
has been trained by study personnel may provide assistance. 
Subjects will also be provided written instructions on how to use the abaloparatide-
SC/Placebo injection pen. Subjects will be instructed by the study site to inspect the contents 
of their injection pen before each injection. If the cartridge contents are not clear and 
colorless, or if the contents contain particles, the subjects will be instructed not to use the pen 
and to contact the study site for further guidance. Injections should be administered in the 
morning and preferably at the same time each day. If a dose is missed, the dose should be 
administered as soon as possible up to 12 hours after the missed injection. Any time 
thereafter, the dose should be skipped and the drug should be administered at the next 
scheduled time the following day. All injections are to be given in the periumbilical region, 
rotating the site of injection each day. If it is deemed medically necessary by the Investigator 
for an injection to be administered at a site other than the abdomen, the alternate site of 
injection is to be recorded and the reason for the change documented in the medical chart and 
eCRF as a protocol deviation. On the first day of study medication administration, the subject 
should self-inject while in a sitting or lying position at the study site and remain in that 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 45 of 81 
position for approximately 5 minutes. Within 5 minutes, and 1 hour post-injection, the 
injection site will be evaluated by the Investigator using the scale provided by RADIUS. The 
subject is to remain under observation for a minimum of 60 minutes after the initial injection. 
An orthostatic blood pressure measurement will be taken 60 minutes after the injection. On 
the days when blood sampling is required after study medication injection, the subject is to 
remain in the vicinity of the clinic for the blood collections scheduled up to 4 hours post-
injection. Subjects are to be instructed to self-inject at home in a location where they have the 
ability to sit or lie down. 
To assess injection site reactions, the location, date, and time that each dose of study 
medication was administered must be recorded by the subject in the diary beginning on Day 2 
and continuing through Day 7 in Month 1 (Visit 4) and beginning on Day 2 and continuing 
through Day 7 in Month 9 and entered in the diary. 
Subjects will be instructed to use a new pen after each 30-day period. At each clinic visit 
during the Treatment Period, the used and unused abaloparatide-SC or placebo injection pens 
must be returned. Compliance, AEs, and use of concomitant medications should be reviewed 
upon drug re-supply and documented accordingly in the drug accountability log and eCRF. 
5.5. 
Treatment Compliance 
To ensure treatment compliance, the Investigator or designee will supervise all study drug 
administration that occurs at the site. At each study visit, the Investigator or designee will 
review subject compliance with study drug administration and remind the subject of study 
drug dosing requirements. Subject compliance will be ascertained by 2 methods: subject 
diaries and measuring the residual drug in the cartridge. 
Discrepancies will be discussed with the subjects, documented in the medical charts, and 
recorded in the eCRF as appropriate. If a subject does not take all study medication 
(abaloparatide-SC, placebo, calcium, and vitamin D supplements), the reason for the missed 
dosing is to be recorded by the subject in their diary. 
If a subject demonstrates continued noncompliance of study drug dosing despite educational 
efforts, the Investigator should contact the Medical Monitor to discuss discontinuation of the 
subject from the study. 
5.6. 
Drug Accountability 
The Investigator or designated site staff will maintain records documenting the dates and 
amounts of the following: 
• Study drug received 
• Study drug dispensed to the subjects 
• Study drug returned by the subjects 
• Study drug returned to RADIUS/designee or destruction of study drug on site 
Subjects will be instructed to return all used and unused study drug to the site. The study drug 
will be retained at the site until inventoried by the study monitor and approved for destruction 
or return. The study monitor will verify study drug records and inventory throughout the 
study. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 46 of 81 
5.7. 
Unblinding of Study Medication 
5.7.1. 
Medical Emergency 
Breaking the treatment blind for a subject should be done only in the event of a medical 
emergency where the identity of study medication is necessary to appropriately treat the 
subject. The Investigator may unblind the treatment received by the subject through the IRT. 
The IRT will automatically document and record any such unblinding and notify the Sponsor 
Medical Monitor of the unblinding event. The study monitor will not be apprised of the actual 
treatment assignment. In addition, the Sponsor Medical Monitor has the ability to unblind the 
study medication in a medical emergency. 
If the Investigator determines that the medical event that resulted in unblinding of the study 
medication is not treatment related (relationship is documented as “none”; see Section 7.1.1 
for definitions of relationship), the subject may continue treatment and participation in the 
study, providing no more than 14 days has elapsed since the last dose of study medication 
(refer to Section 4.7 for details regarding temporary suspension of treatment). If the subject 
discontinues from further treatment with study medication, they should undergo the 
Month 12/Early Termination and the Month 13 Follow-up Visit as outlined in Section 6.2.7, 
and the Schedule of Assessments and Procedures (Table 3). 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 47 of 81 
6. 
STUDY PROCEDURES AND SCHEDULE 
6.1. 
Study Procedures 
6.1.1. 
Study-Specific Procedures 
The study-specific assessments are detailed in this section and outlined in Table 3. Any 
results falling outside of the reference ranges may be repeated once time during the Screening 
Period at the discretion of the Investigator. 
6.2. 
Study Schedule 
This study is comprised of 9 clinic visits. Study assessments are to be performed according to 
the Schedule of Assessments and Procedures (Table 3). There is a ± 4-day window for each 
clinic visit. 
The study will consist of a Screening Period (up to 2 months), a Pretreatment Period 
(1 week), a Treatment Period (12 months), and a Follow-up Visit (1 month). During the 
Treatment Period, subjects will have clinic visits for study-related protocol procedures at 
Day 1, Month 1, Month 3, Month 6, Month 9, and Month 12. The active phase of the study 
will be considered complete when the last subject undergoes the last visit. For the purpose of 
this study, 1 month is equal to 30 days. 
6.2.1. 
Schedule of Assessments and Procedures 
A comprehensive Schedule of Assessments and Procedures is presented in Table 3. 
Due to the ongoing COVID-19 pandemic, arrangements may also be made, contingent on the 
subject’s consent and in compliance with country, state, and local requirements, to have a 
study visit conducted at the subject’s home by site staff. If this occurs, blood and/or urine 
samples may be collected at the subject’s home and then sent to the central laboratory for 
processing and analysis. Study drug may also be delivered to the subject’s home, if needed, to 
enable the subject to continue administering their study drug daily. 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
 
 
 
 
Page 48 of 81 
 
Table 3: 
Schedule of Assessments and Procedures 
 
Visit 
1 
2 
3 
4 
5 
 
6 
7 
8 
9 
Procedure 
Study Day/Month: 
Screening 
Pretreatmen
t 
Day 1 
Month 
1 
Month 3 
Month 
6 
Month 9 
Month 12/ 
Early 
Termination 
Month 13 
Follow-
up 
Visit Window (Days) 
N/A1 
± 4 
± 4 
± 4 
± 4 
± 4 
± 4 
± 4 
± 7 
Informed consent 
X 
 
 
 
 
 
 
 
 
Verification of entry criteria 
X 
X 
 
 
 
 
 
 
 
Physical examination 2 
X 
 
 
 
 
 
 
 
 
Review of medical history 3 
X 
 
 
 
 
 
 
 
 
Symptom-directed physical 
examination 
 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signs4 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Weight measurement 
X 
 
X 
X 
 
X 
 
X 
 
Height measurement5 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Electrocardiogram6 
X 
 
X 
 
 
 
 
X 
X 
Urinalysis (dipstick)7 
X 
 
 
X 
 
X 
 
X 
 
Chemistry blood collection 
X 
 
 
X 
 
X 
 
X 
 
Hematology blood collection 
X 
 
 
X 
 
X 
 
X 
 
Coagulation (PT and PTT) blood 
collection 
X 
 
 
 
 
 
 
X 
 
PTH (1–84) 
X 
 
 
 
 
 
 
X 
 
25-hydroxyvitamin D level 
X 
 
 
 
 
 
 
X 
 
1,25-dihydroxy vitamin D level 
X 
 
 
 
 
 
 
X 
 
Total testosterone and SHBG 
X 
 
 
 
 
 
 
X 
 
Estradiol 
X 
 
 
 
 
 
 
 
 
Thyroid stimulating hormone8 
X 
 
 
 
 
 
 
 
 
PK samples (see Table 4) 
 
 
 
 
 
X 
X 
X 
 
Study medication assignment via IRT 
 
 
X 
 
 
 
 
 
 
Injection training for subjects 
 
X 
 
 
 
 
 
 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
 
Study BA058-05-019 Amendment 6 
 
 
 
 
 
Page 49 of 81 
Table 3: 
Schedule of Assessments and Procedures (Continued) 
 
Visit 
1 
2 
3 
4 
5 
 
6 
7 
8 
9 
Procedure 
Study 
Day/Month: 
Screening Pretreatment 
Day 1 
Month 
1 
Month 3 
Month 
6 
Month 9 
Month 12/ 
Early 
Termination 
Month 13 
Follow-up 
Visit Window (Days) 
N/A1 
± 4 
± 4 
± 4 
± 4 
± 4 
± 4 
± 4 
± 7 
Calcium and vitamin D supplements 
 
Daily administration 
 
Study medication administration 
 
 
Daily administration 
 
Serum markers of bone metabolism  
(s-PINP and s-CTX) 
 
 
X 
X 
X 
X 
 
X 
 
Serum calcium and albumin9 
 
 
X 
X 
X 
X 
X 
 
 
24-hour urine collection (for 
calcium:creatinine and creatinine 
clearance)10 
 
 
X 
 
X 
 
 
 
 
Radiologic (lumbar and thoracic 
vertebrae) assessments 
X 
 
 
 
 
 
 
 
 
Symptom driven spinal radiologic 
assessment 
 
At any time 
Clinical assessment of new fractures11 
 
X 
X 
X 
X 
X 
X 
X 
 
BMD of lumbar spine, total hip, and 
femoral neck by DXA12 
X 
 
 
 
X 
X 
 
X 
 
BMD of wrist by DXA13 
 
 
X 
 
X 
X 
 
X 
 
vBMD of hip by QCT14 
 
 
X 
 
 
 
 
X 
 
Sample for immunogenicity testing15 
 
 
X 
X 
X 
X 
X 
X 
X 
Investigator assessment of local 
tolerance (dermal reactions assessment) 
 
 
X 
X 
X 
X 
X 
 
 
Subject assessment of local tolerance16 
 
 
X 
 
 
 
X 
 
 
Subject diary review17 
 
 
X 
X 
X 
X 
X 
X 
 
Document AEs and concomitant18 
medications  
At any time, question subjects at every visit 
Drug supply/resupply/accountability 
 
 
X 
X 
X 
X 
X 
X 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
 
Study BA058-05-019 Amendment 6 
 
 
 
 
 
Page 50 of 81 
1. The window for screening activities is 60 days. Due to the ongoing COVID-19 pandemic or other local/widespread emergencies, if there is a delay in the screening process 
that would result in a subject remaining in screening for greater than 60 days, the Medical Monitor should be contacted. All safety laboratory results must be reported 
within 30 days prior to randomization. 
2. A complete physical examination includes a review of the following systems: head/neck/thyroid, eyes/ears/nose/throat, respiratory, cardiovascular, lymph nodes, abdomen, 
skin, musculoskeletal, and neurological. Breast, anorectal, and genital examinations will be performed when medically indicated. After screening, any clinically 
significant abnormal findings in physical examinations should be reported as AEs. 
3. Including alcohol and tobacco use assessment. 
4. Blood pressure, heart rate, body temperature, and respiration rate are to be recorded predose at each study visit. Only blood pressure, heart rate and respiration rate are to be 
recorded one-hour post dose at each study visit during the Treatment Period. All blood pressure assessments need to be orthostatic. 
5. Height is to be measured at each visit in the standing position using a medical stadiometer. 
6. ECGs are to be performed predose and one-hour postdose during the Treatment Period. 
7. All routine urinalysis will be performed on a sample freshly voided during the visit and sent to a central lab for microscopy if test is positive for micro-organisms via 
dipstick. 
8. Reflex testing of T3 and free T4 will be performed by the central laboratory for any out-of-range TSH result. 
9. Serum calcium and albumin will be measured predose from the standard chemistry panel on Month 1 and Month 6, and from a separate blood draw at Day 1, Month 3 and 
Month 9 and 4 hours post dose at Day 1, Month 1, Month 3, Month 6, and Month 9. 
10. A 24-hour urine collection will be collected at Day 1 and Month 3 and will be used for urinary calcium and urinary creatinine measurements. Subjects will discard the 
first void and begin a 24-hour urine collection on the day prior to the clinic visit. 
11. If the subject reports that a fracture has occurred, remind the subject to bring X-rays and any medical reports of the fracture to the next clinic visit. Documentation must 
be obtained on all new fractures that occur during the study. This documentation should be maintained in the source documents. 
12. Each DXA for a given subject should be performed on the same machine, and if available, preferably by the same technician. For screening purposes, DXA scans of the 
lumbar spine, total hip, and femoral neck taken up to 35 days prior to the beginning of the Screening Period, with a study-approved scanner, may be used to determine 
study eligibility. 
13. The first wrist DXA will be performed prior to study drug administration on Day 1 and should be performed on the same machine, and if available, preferably by the 
same technician. 
14. QCT performed in a subset of subjects at selected study sites. 
15. Samples will be drawn prior to treatment on Day 1, Months 1, 3, 6, 9, and 12, and the Follow-up Visit scheduled at 1 month after the last dose of study medication. 
16. The subject will maintain a diary of their assessment of local tolerance beginning on Day 2 and continuing through Day 7 in Month 1, and beginning on Day 2 and 
continuing through Day 7 in Month 9. 
17. The subject medication diary will be reviewed by study personnel at each study visit to ensure subject compliance. 
18. AEs and SAEs will be recorded on the case report forms starting from the time of subject entry into the Screening Period (Visit 1) of the study (signed informed consent) 
until 30 days after the last dose of study medication. All AEs will be followed until resolution or stabilization. Any SAEs that occur at any time after completion of the 
study, which are considered by the Investigator to be related to study treatment, must be reported to the Sponsor or its designee. 
 
AE = adverse event; BMD = bone mineral density; DXA = dual energy X-ray absorptiometry; IRT = Interactive response technology; PT = Prothrombin time; PTH = 
Parathyroid hormone; PTT = Partial thromboplastin time; QCT = quantitative CT; s-CTX = serum carboxyl-terminal cross-linking telopeptide of type I collagen; s-PINP = 
serum procollagen type I N-terminal propeptide; SAE = serious adverse event; SHBG = Sex hormone binding globulin; vBMD = volumetric bone mineral density 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
 
Study BA058-05-019 Amendment 6 
 
 
 
 
 
Page 51 of 81 
Table 4: 
Schedule for Pharmacokinetic Sample Collections 
Study Visit 
Predose 
Postdose 
Within 10 min 
before injection 
20 min ±  
10 min 
45 min ±  
15 min 
1.5 hours 
± 0.5 hours 
2.5 hours 
± 0.5 hours 
4 hours 
± 0.5 hours 
Month 6 
X 
 
X 
 
Month 9 
 
X 
 
 
X 
Month 12 
X 
 
X 
 
 
Note: This schedule only applies to those subjects who consent to have PK samples collected during the study. 
min = minute; PK = pharmacokinetics 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
Study BA058-05-019 Amendment 6 
 
Page 52 of 81 
6.2.2. 
Informed Consent Process 
Each subject must sign and date a study-specific informed consent form (ICF) before any study-
specific procedures can be performed. The consent forms will comply with all applicable 
regulations governing the protection of human subjects. An ICF, approved by RADIUS and the 
site's IRB/IEC must be used. The Investigator or designee must record the date when the ICF 
was signed in the subject’s source document. 
6.2.3. 
Assigning Subject Numbers 
Once a subject has signed an ICF, a subject number will be assigned. The subject will retain this 
number for the entire study. 
6.2.4. 
Subject and Disease Characteristics 
Subject and disease characteristics include the following: demographics, medical history, height, 
and weight. 
Medical history will be elicited from each subject during screening. Based on the medical 
history, the subject will be assessed for any disqualifying medical conditions as specified in the 
inclusion and exclusion criteria. The medical history shall include a complete review of systems, 
past medical and surgical histories, and any allergies. 
Subjects included into the study based on a history of low-trauma nonvertebral fractures must 
have sufficient source documentation in the form of a medical report or radiographic films as 
evidence of such history.  
6.2.5. 
Screening Period (Visit 1) 
Signed informed consent will be obtained and eligibility for study entry assessed. The following 
baseline screening evaluations will be performed: 
• Physical examination 
• Review of medical history, including alcohol, tobacco, and drug use 
• Review of concomitant medications 
• Height 
• Weight 
• ECG 
• Orthostatic blood pressure and vital signs 
• Lumbar and thoracic spine radiographs (anteroposterior and lateral) 
• BMD assessments of lumbar spine, total hip, and femoral neck by DXA 
− BMD T scores may be rounded off to the nearest tenth (i.e., rounded off to one 
decimal point) for the purpose of assessing study eligibility per protocol. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 53 of 81 
− For screening purposes, DXA scans of the lumbar spine, total hip, and femoral 
neck taken with a study-approved scanner up to 35 days prior to the beginning of 
the Screening Period may be used to determine subject eligibility. 
• Laboratory testing of serum chemistry, hematology, coagulation, and urine dipstick 
• PTH, 25-hydroxyvitamin D, and 1,25-dihydroxy vitamin D level 
• Serum total testosterone and sex hormone binding globulin (SHBG) 
• Estradiol and TSH level 
Subjects who do not meet the 25-hydroxyvitamin D entry criterion may receive vitamin D 
supplementation and be retested once during the Screening Period. Similarly, subjects with 
minor elevations of PTH may be retested one time after vitamin D supplementation. Subjects 
whose laboratory tests do not fall within the specified ranges as detailed in the 
inclusion/exclusion criteria may have the samples redrawn and the tests repeated once during the 
Screening Period. If upon retesting, the values fall within the inclusion/exclusion criteria, the 
subject may enter the study. All subjects enrolled following retesting must have safety laboratory 
results reported within 30 days prior to randomization.  
The window for screening activities is 60 days. Due to the ongoing COVID-19 pandemic or 
other local/widespread emergencies, there may be screening process delays. In the case of 
screening process delays that result in a subject remaining in the Screening Period for greater 
than 60 days, the Medical Monitor should be contacted. All safety laboratory results must be 
reported within 30 days prior to randomization. 
Any AEs will be recorded beginning on the day that the subject signs the informed consent. 
6.2.6. 
Pretreatment Period (Visit 2) 
Subjects who are eligible for the study on the basis of screening evaluations will enter the 
Pretreatment Period of the study and will be provided the calcium and vitamin D supplements 
required until the next study visit. All subjects will be required to commence calcium 500–
1000 mg/day and vitamin D supplements 400–800 IU/day (or doses determined by the 
Investigator and agreed by the Sponsor Medical Monitor, according to the subject’s need). 
Subjects will also undergo training for medication self-administration during this period; AEs 
will be recorded, and the following procedures will be performed: 
• Symptom-directed physical exam, including assessment for potential vertebral 
fracture 
• Verification of study entry criteria 
• Height 
• Orthostatic blood pressure and vital signs 
• Clinical assessment of new fractures 
• Instruct subject on procedures and provide with supplies for collecting a 24-hour 
urine sample (the sample is to be collected on the day prior to Day 1) 
• Injection training for subjects 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 54 of 81 
6.2.7. 
Treatment Period 
Subjects who remain eligible for study participation will be randomly allocated through the IRT, 
using a 2:1 randomization ratio on Day 1 to receive treatment with either blinded abaloparatide-
SC 80 µg per day or daily 80-μg placebo injections, respectively. Treatment will be blinded to 
the Sponsor, subjects, and Investigators throughout the study except in a medical emergency 
where the identity of study medication is necessary to appropriately treat the subject 
(Section 5.7). The Sponsor pharmacovigilance/regulatory personnel may also be unblinded for 
SUSAR reporting purposes. During the Treatment Period, subjects will self-administer a single 
subcutaneous dose of study medication once a day.  
At each clinic visit during this period, recent health status will be obtained, the diary reviewed, 
AEs collected, and orthostatic blood pressure and vital signs performed. Laboratory assessments 
of chemistry and hematology and urinalyses will be obtained at Month 1, Month 6, and 
Month 12, and a 24-hour urine will be collected on the day prior to Visit 1 and on the day prior 
to Visit 5 (Month 3). Clinical assessments for fracture will be performed at each visit. Source 
documentation (imaging report and/or film along with other supporting documentation as 
appropriate) will be collected from each site to confirm fracture. 
Subjects will have BMD assessed by DXA at the lumbar spine, total hip, and femoral neck at 
screening and Months 3, 6 and 12, and at the wrist on Day 1 and Months 3, 6 and 12. Volumetric 
BMD at the hip will be assessed by QCT on Day 1 and at Month 12. QCT will be performed in a 
subset of subjects at a selected number of study sites based upon availability. Bone turnover 
marker assessments (s-PINP and s-CTX) will be performed on Day 1, and Months 1, 3, 6, and 
12.  
6.2.8. 
Visit 3 (Day 1) 
• A 24-hour urine collection will be collected. Subjects will discard the first void and 
begin a 24-hour urine collection on the day prior to the clinic visit 
• Symptom driven physical exam, including assessment for potential vertebral fracture 
• Collect blood for immunogenicity testing 
• ECGs (predose and one-hour postdose) 
• Orthostatic blood pressure and vital signs 
• Height 
• Weight 
• Serum calcium and albumin (predose and 4 hours post dose) 
• Measurement of volumetric bone density at the hip by QCT 
• Clinical assessment of new fractures 
• AE and concomitant medication review 
• Wrist DXA 
• Bone turnover markers (s-PINP and s-CTX) 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 55 of 81 
• Randomization and study medication (abaloparatide-SC or placebo) will be assigned 
through the IRT 
• Dispense study medication 
• First dose of study medication will be administered by the subject in clinic 
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration 
• Instruct subject on completion of diary, including subject assessment of local 
tolerance, within 5 minutes and at 1 hour following administration, will need to be 
done beginning on Day 2 and continuing through Day 7 of Month 1. 
6.2.9. 
Visit 4 (Month 1) 
• Symptom driven physical exam, including assessment for potential vertebral fracture 
• Collect blood for immunogenicity testing 
• Orthostatic blood pressure and vital signs 
• Height 
• Weight 
• Laboratory testing of serum chemistry, hematology, and urine dipstick 
• Serum calcium and albumin (predose and 4 hours post dose) 
• Dispense study medication 
• Self-administration of study medication when directed by site staff after completion 
of predose activities 
• Clinical assessment of new fractures 
• AE and concomitant medication review 
• Bone turnover markers (s-PINP and s-CTX) 
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration 
• Review subject diary 
• Provide subject with supplies for collecting a 24-hour urine sample (the sample is to 
be collected on the day prior to the Month 3 visit). 
6.2.10. 
Visit 5 (Month 3) 
• A 24-hour urine collection will be collected. Subjects will discard the first void and 
begin a 24-hour urine collection on the day prior to the clinic visit 
• Symptom-directed physical examination, including assessment for potential vertebral 
fracture 
• Collect blood for immunogenicity testing 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 56 of 81 
• Orthostatic blood pressure and vital signs 
• Height 
• BMD assessments of lumbar spine, total hip, femoral neck, and wrist by DXA 
• Bone turnover markers (s-PINP and s-CTX) 
• Dispense study medication 
• Self-administration of study medication when directed by site staff after completion 
of predose activities 
• Serum calcium and albumin (predose and 4 hours post dose) 
• Clinical assessment of new fractures 
• AE and concomitant medication review 
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration 
• Review subject diary 
6.2.11. 
Visit 6 (Month 6) 
• Symptom-directed physical examination, including assessment for potential vertebral 
fracture 
• Collect blood for immunogenicity testing 
• Height 
• Weight 
• Orthostatic blood pressure and vital signs 
• Dispense study medication 
• Self-administration of study medication when directed by site staff after completion 
of predose activities 
• Only for subjects who consent to provide PK samples: Collect PK samples at 45 
minutes (±15 minutes) and 2.5 hours (±0.5 hour) after injection 
• Laboratory testing of serum chemistry, hematology, and urine dipstick 
• Serum calcium and albumin (predose [from chemistry panel] and 4 hours post dose) 
• BMD assessments of lumbar spine, total hip, femoral neck, and wrist by DXA 
• Bone turnover markers (s-PINP and s-CTX) 
• Clinical assessment of new fractures 
• AE and concomitant medication review 
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 57 of 81 
• Review subject diary 
6.2.12. 
Visit 7 (Month 9) 
• Symptom-directed physical examination, including assessment for potential vertebral 
fracture 
• Collect blood for immunogenicity testing 
• Orthostatic blood pressure and vital signs 
• Height 
• Dispense study medication 
• Self-administration of study medication when directed by site staff after completion 
of predose activities 
• Only for subjects who consent to provide PK samples: Collect PK samples at 20 
minutes (±10 minutes) and 4 hours (±0.5 hour) after injection 
• Serum calcium and albumin (predose and 4 hours postdose) 
• Clinical assessment of new fractures 
• AE and concomitant medication review 
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration Instruct subject on completion of diary, including subject assessment 
of local tolerance, within 5 minutes and at 1 hour following administration, beginning 
on Day 2, and continuing through Day 7 in Month 9 
• Review subject diary 
6.2.13. 
Visit 8 (Month 12)/Early Termination Visit 
• Symptom-directed physical examination, including assessment for potential vertebral 
fracture 
• Collect blood for immunogenicity testing 
• ECG 
• Weight 
• Height 
• Orthostatic blood pressure and vital signs 
• Only for subjects who consent to provide PK samples and attend the Month 12 visit: 
Collect a predose sample within 10 minutes before injection 
• Self-administration of study medication when directed by site staff after completion 
of predose activities using medication dispensed at Visit 7 (Note: Applicable only to 
subjects completing a Month 12 visit) 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 58 of 81 
• Only for subjects who consent to provide PK samples and attend the Month 12 visit: 
Collect a postdose sample at 1.5 hours (±0.5 hour) after injection 
• PTH, 25-hydroxyvitamin D, and 1,25-dihydroxy vitamin D level 
• Laboratory testing of serum biochemistry, hematology, coagulation and urine dipstick 
• BMD assessments of lumbar spine, total hip, femoral neck, and wrist by DXA 
• Measurement of volumetric bone density at the hip by QCT 
• Bone turnover markers (s-PINP and s-CTX) 
• Serum total testosterone and SHBG 
• Clinical assessment of new fractures 
• AE and concomitant medication review 
• Review subject diary 
6.2.14. 
Visit 9/Safety Follow-up 
• Symptom-directed physical examination, including assessment for potential vertebral 
fracture 
• Collect blood for immunogenicity testing 
• Record vital signs 
• Height 
• ECG 
• All AEs, including SAEs, will be recorded from the time of signing of the informed 
consent and up to the 30 days after the last dose of study medication 
• All subjects who remain antibody positive will continue to be followed for 
immunogenicity testing every 6 months until their result is antibody negative 
6.2.15. 
Unscheduled Visit 
If the subject returns to the clinic for an unscheduled visit (e.g., to follow-up on an abnormal 
laboratory test), the procedures performed at this visit will be recorded in the eCRF and source 
documentation. 
6.3. 
Vital Signs and Physical Examinations 
A complete physical examination (review of all body systems), height, weight, and vital signs 
assessment will be performed at screening. 
A complete physical examination includes a review of the following systems: head/neck/thyroid, 
eyes/ears/nose/throat, respiratory, cardiovascular, lymph nodes, abdomen, skin, musculoskeletal, 
and neurological. Breast, anorectal, and genital examinations will be performed when medically 
indicated. After screening, any clinically significant abnormal findings in physical examinations 
should be reported as AEs. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 59 of 81 
Height and weight will be measured with shoes off. Height is to be measured using a wall 
mounted stadiometer. When height cannot be accurately measured such as in cases of severe 
kyphosis or loss of height from vertebral compression fractures, a documented historical height 
(i.e., from government IDs, medical records, etc.) may be used. 
Vital signs include orthostatic blood pressure (systolic and diastolic), temperature (oral), heart 
rate, and respiratory rate. These will be assessed following a 5-minute rest (seated or supine) and 
before blood sample collection. At visits when study drug is administered at the site, vital sign 
assessments will be collected before the dose of study drug. Supine and standing blood pressure 
measurements will be performed at each visit during the Treatment Period.  
6.4. 
12-Lead Electrocardiogram 
Standard, 12-lead ECGs will be performed. A hard copy of the ECG should be printed and 
signed by the Investigator at the site. Any abnormalities should be noted and clinical relevance 
should be documented. An ECG will be recorded immediately prior to dosing and 1 hour 
postdose during the Treatment Period. 
6.5. 
Laboratory Evaluations 
6.5.1. 
Clinical Laboratory Evaluations 
Hematology, serum chemistry, and urinalysis will be collected at time points indicated in the 
Schedule of Assessments and Procedures in Table 3. All clinical laboratory blood and 24-hour 
urine samples will be sent to a central laboratory for analysis and testing. A list of study clinical 
laboratory tests is in Table 5. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 60 of 81 
Table 5: 
Clinical Laboratory Tests 
Hematology 
 
Serum Chemistry 
Urinalysis (Dipstick)a 
Additional Tests 
Hemoglobin 
Sodium 
pH 
PTH (1–84)b 
Hematocrit 
Potassium 
Glucose 
25-hydroxyvitamin Db 
1,25-dihydroxy vitamin Db 
 
WBC count with 
differential in absolute 
counts 
Chloride 
Protein 
BSAP 
RBC count 
Inorganic phosphorus 
Ketones 
Estradiolc 
Testosteroneb 
SHBG b 
TSH (T3 and Free T4)c 
MCV 
Albumin 
Bilirubin 
MCHC 
Total protein 
Blood 
MCH 
Glucose 
Urobilinogen 
Platelet count 
BUN 
Specific gravity 
 
Creatinine 
Nitrite 
 
Uric acid 
Leukocytes 
 
AST 
 
 
ALT 
 
 
GGT 
 
 
CPK 
 
 
Alkaline phosphatase 
 
 
Total bilirubin 
 
 
LDH 
 
 
Total Cholesterol  
 
 
Triglycerides 
 
 
Total calcium 
 
a. Clinic only, if required by PI send to central lab for microscopy 
b. Only required at Screening and Visit 8 or early termination (Month 12 visit)  
c. Only required at Screening. Reflex testing for T3 and Free T4 will be performed by the central laboratory if TSH 
is outside the normal limits. Reflex testing for bone-specific alkaline phosphatase will be performed by the 
central laboratory if serum alkaline phosphatase is outside the normal limits. 
ALT = alanine aminotransferase; AST = Aspartate aminotransferase; BSAP = bone-specific alkaline phosphatase; 
BUN = blood urea nitrogen; CPK = Creatine phosphokinase; GGT = gamma-glutamyl transpeptidase; LDH = 
lactate dehydrogenase; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin 
concentration; MCV = Mean corpuscular volume; PTH = parathyroid hormone; RBC = red blood cell; SHBG = sex 
hormone binding globulin; TSH = thyroid stimulating hormone; WBC = white blood cell 
In the event of medically significant, unexplained, or abnormal clinical laboratory test values, the 
test(s) should be repeated and followed up until the results have returned to within the normal 
range or an adequate explanation for the abnormality is found. Clinically significant changes in 
laboratory tests that occur during the course of the study are to be reported as AEs. 
The clinical laboratory will clearly mark all laboratory test values that are outside the normal 
range and the Investigator will indicate the clinical relevance of these out-of-range values. 
6.5.2. 
Serum Markers of Bone Metabolism 
Blood samples will be taken to measure efficacy related markers of bone metabolism at Day 1, 
Month 1, Month 3, Month 6, and Month 12 or early termination. S-PINP and s-CTX will be 
measured in all subjects. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 61 of 81 
6.5.3. 
Immunogenicity Testing 
Serum samples for immunogenicity testing will be collected at Day 1 (Visit 3), Month 1 
(Visit 4), Month 3 (Visit 5), Month 6 (Visit 6), Month 9 (Visit 7), Month 12 (Visit 8), and the 
Follow-up Visit scheduled at 1 month after the last dose of study medication (Visit 9). Samples 
will be tested for the presence of binding anti-abaloparatide antibodies, including determination 
of antibody titer. Any positive samples will be tested for the potential to neutralize abaloparatide 
in a cell-based assay. Additionally, positive samples will be tested for cross-reactivity to 
endogenous PTH and PTHrP. Any subjects who show presence of antibodies at the Follow-up 
Visit scheduled at 1 month following the last dose of study medication (Visit 9) will be retested 
at 6-month intervals post-study until antibody status return to negative. 
The serum samples for immunogenicity testing will be analyzed and reported separately. All the 
planned analyses related to the immunogenicity results and antibody status will also be reported 
separately. 
6.5.4. 
Pharmacokinetic Testing 
A blood sample for PK analysis of abaloparatide will be collected using a 5 mL K3 EDTA tube 
with 0.1 mg/mL aprotinin at each time point indicated in the PK sample collection schedule 
(Table 4). 
6.5.5. 
Specimen Preparation, Handling and Storage 
The procedures for the collection, handling, and shipping of clinical laboratory samples are 
specified in a separate Laboratory Manual provided to each clinical site. 
6.6. 
Imaging Procedures 
All imaging measurements (BMD according to DXA and QCT) will be performed according to 
the procedures outlined in the Imaging Charter and Imaging Manuals which will be provided as a 
separate document. A central imaging laboratory will be utilized for all DXA and QCT readings. 
QCT will be performed in a subset of subjects at a selected number of study sites. 
6.6.1. 
Dual Energy X-ray Absorptiometry 
All subjects will have areal bone density (aBMD) measurements taken via DXA of the lumbar 
spine, total hip, femoral neck, at Screening (Visit 1), wrist at Day 1 (Visit 3); spine, total hip, 
femoral neck, and wrist at Month 3 (Visit 5), Month 6 (Visit 7), and Month 12 (Visit 8). Lumbar 
spine scans must include L1 through L4. Hip scans will include the entire proximal femur to 
about 2 cm below the lesser trochanter. DXA bone density assessments will be performed at the 
forearm to measure BMD of the distal one-third radius and ultra-distal radius. For hip and wrist 
scans, the same side should be used for all scans at all visits. If a subject fractures a hip or 
forearm being examined during the study, no further scans of either hip or forearm will be 
acquired. 
For screening purposes, DXA scans of the lumbar spine, total hip, and femoral neck taken up to 
35 days prior to the beginning of the Screening Period may be used to determine study 
eligibility. DXA scans should be performed using a study-approved scanner (and read by the 
study central DXA reader) up to 35 days prior to the subject’s Screening Visit. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 62 of 81 
6.6.2. 
Quantitative Computed Tomography 
A subset of subjects at a selected number of study sites will have volumetric BMD (vBMD) 
measurements taken via QCT of the hip on Day 1 (Visit 3) and Month 12 (Visit 8). 
6.6.3. 
Clinical and Radiologic Evaluation of Fractures 
All spine radiographs will be performed according to the procedures outlined in the Imaging 
Charter and Imaging Manual which will be provided as separate documents. All subjects will 
have X-rays taken to document fractures of the lumbar and thoracic vertebrae at Screening to 
confirm entry criteria. Radiographs of the lateral thoracic and lumbar spine will include coverage 
of T3 to S1. The lateral spine radiographs will be assessed for prevalent and incident vertebral 
fractures using the Genant Semiquantitative Scoring method (Genant et al, 1993). 
• Grade 0: Normal (approximately < 20% reduction in anterior, middle, or posterior 
height) 
• Grade 1: Mild fracture (approximately 20%–25% reduction in anterior, middle, or 
posterior height) 
• Grade 2: Moderate fracture (approximately 25%–40% reduction in anterior, middle, 
or posterior height) 
• Grade 3: Severe fracture (> 40% reduction in anterior, middle, or posterior height) 
Incident radiological vertebral fractures occur in vertebrae with an increase in SQ score ≥ 1 at a 
Follow-up Visit. New incident radiological vertebral fractures occur in vertebrae that are not 
fractured (i.e., SQ score of 0) at Screening. Worsening incident radiological vertebral fractures 
occur in vertebrae with prevalent (i.e., pre-existing) fractures at baseline. Subjects will also be 
clinically evaluated for vertebral and nonvertebral fractures (wrist, hip, rib, etc.) which occur 
during the study. Should a clinical fracture occur, X-ray images and reports associated with the 
fracture must be obtained and maintained in the subject’s medical record. 
All fractures will be identified and evaluated as part of the disease assessment and will be 
documented in the case report forms and source documents. 
6.7. 
Discontinuation from the Study 
Subjects may voluntarily discontinue from the study for any reason at any time. 
Any subject who demonstrates decreases in BMD ≥ 7% from baseline of this study at the lumbar 
spine or total hip will have the assessment repeated and, if confirmed, will be notified by the 
Investigator, and be withdrawn from the study. Subjects sustaining a radiologically confirmed 
incident vertebral or nonvertebral fragility fracture will be informed of the finding and will be 
counseled as to treatment options and may discontinue or choose to remain on the study. Those 
subjects who sustain an incident fracture during the study and elect to remain in the study will be 
asked to sign an additional informed consent document advising them of an increased risk for 
subsequent fracture.  
Subjects who decide they do not wish to participate in the study further should return for the 
assessments indicated for the Month 12/Early Termination and 30 days later for the 
Month 13/Follow-up Visit in the Schedule of Assessments and Procedures (Table 3). If they fail 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 63 of 81 
to return for these assessments for unknown reasons, every effort (e.g., telephone, email, and 
letter) should be made to contact them. 
6.7.1. 
Withdrawal of Consent 
Subjects may voluntarily withdraw consent to participate in the study for any reason at any time. 
Withdrawal of consent occurs only when a subject does not want to participate in the study 
anymore and does not want any further visits or assessments and does not want any further 
study-related contact. 
If a subject withdraws consent, the Investigator must make every effort to determine the primary 
reason for this decision and record this information. Further attempts to contact the subject are 
not allowed unless safety findings require communicating or follow-up. 
6.7.2. 
Early Study Termination 
The study can be terminated at any time for any reason by the Sponsor. Should this be necessary, 
subjects should be seen as soon as possible and treated as a prematurely withdrawn subject. The 
Investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the subject’s interests. 
The Investigator will be responsible for informing IRBs/IECs of the early termination of the 
study. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 64 of 81 
7. 
ADVERSE EVENT AND SERIOUS ADVERSE EVENT 
DOCUMENTATION 
7.1. 
Evaluation of Safety 
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects and is mandated by regulatory agencies worldwide. All 
clinical studies sponsored by RADIUS will be conducted in accordance with Standard Operating 
Procedures (SOPs) that have been established to conform to regulatory requirements worldwide 
to ensure appropriate reporting of safety information. 
All AEs are collected from the time of the informed consent until 30 days after last dose of 
investigational product. Where possible, a diagnosis rather than a list of symptoms should be 
recorded. All AEs should be captured on the appropriate AE pages in the eCRF and in source 
documents. The Investigator will assess all AEs for relationship to study drug. For information 
on the safety profile obtained to date for abaloparatide, please refer to the IB. 
7.1.1. 
Adverse Event 
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH, 
1995). 
AEs include: 
• Worsening (change in nature, severity, or frequency) of conditions present at the 
onset of the study 
• Intercurrent illnesses 
• Drug interactions 
• Events related to or possibly related to concomitant medications 
• Abnormal laboratory values (this includes significant shifts from Baseline within the 
range of normal that the Investigator considers to be clinically important) 
• Clinically significant abnormalities in physical examination, vital signs, and weight 
An abnormal laboratory value will not be assessed as an AE unless it requires a therapeutic 
intervention or is considered by the Investigator to be clinically significant. 
7.1.2. 
Serious Adverse Event 
A SAE is any AE that results in any of the following: 
• Death 
• Life-threatening: The term “life-threatening” in the definition of “serious” refers to an 
event/reaction in which the subject was at risk of death at the time of the 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 65 of 81 
event/reaction; it does not refer to an event/reaction which hypothetically might have 
caused death if it were more severe. 
• Required in-subject hospitalization or prolongation of existing hospitalization 
• A persistent or significant disability/incapacity (i.e., substantial disruption of the 
ability to conduct normal life function) 
• Congenital anomaly/birth defect 
Important medical events that may not result in death, are life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in in-subject hospitalization, or the development of drug 
dependency or drug abuse.  
All AEs of osteosarcoma will be reported as SAEs. All reports of osteosarcoma, regardless of 
causality or expectedness, will be expedited to the FDA within 15 days of receipt. MedDRA 
preferred terms include osteosarcoma, osteosarcoma metastatic, osteosarcoma recurrent, 
extraskeletal osteosarcoma, extraskeletal osteosarcoma metastatic, extraskeletal osteosarcoma 
recurrent. 
All treatment-related SAEs must be followed until resolution (subject has returned to baseline 
status of health) or until stabilization (the Investigator does not expect any further improvement 
or worsening of the reported event). 
7.1.3. 
Recording an Adverse Event 
All AEs/SAEs will be entered into the electronic database. 
Planned hospital admissions or surgical procedures for an illness or disease that existed before 
the subject was enrolled in the study are not to be considered AEs unless they occur at a time 
other than the planned date or the pre-existing illness or disease worsens after enrollment into the 
study. 
Fractures identified during the study are not to be recorded as AEs unless the subject is 
hospitalized, the fracture is complicated, or the Investigator considers the fracture to be unrelated 
to the subject’s underlying osteoporosis. All fractures will be identified and evaluated as part of 
the disease assessment and will be documented in the CRF and by collection of source 
documents. 
For both serious and non-serious AEs, the Investigator must determine the intensity of the event 
and the relationship of the event to study drug administration (abaloparatide and placebo). 
Intensity for each AE will be defined according to the following criteria: 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
 
 
Intensity 
Definition  
Mild 
Awareness of sign or symptom, but easily 
tolerated. 
Moderate  
Discomfort enough to cause interference 
with normal daily activities. 
Severe 
Inability to perform normal daily activities. 
If the intensity of an adverse event changes within a day, the maximum intensity should be 
recorded. If the intensity changes over a longer period of time, the changes should be recorded as 
separate events (having separate onset and stop dates for each intensity). 
Relationship to blinded study drug administration will be determined by the Investigator 
according to the following criteria: 
Relationship 
Definition  
None 
No relationship between the event and the 
administration of study drug. The event is 
related to other etiologies, such as 
concomitant medications or subject’s 
clinical state. 
Unlikely 
The current state of knowledge indicates that 
a relationship to study drug is unlikely or the 
temporal relationship is such that study drug 
would not have had any reasonable 
association with the observed event. 
Possible 
A reaction that follows a plausible temporal 
sequence from administration of the study 
drug and follows a known response pattern 
to the suspected study drug. The reaction 
might have been produced by the subject’s 
clinical state or other modes of therapy 
administered to the subject. 
Probable 
A reaction that follows a plausible temporal 
sequence from administration of the study 
drug and follows a known response pattern 
to the suspected study drug. The reaction 
cannot be reasonably explained by the 
known characteristics of the subject’s 
clinical state or other modes of therapy 
administered to the subject. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 67 of 81 
For the purpose of safety analyses, all AEs that are classified with a relationship to study 
medication administration of possible or probable will be considered treatment-related events. 
7.1.3.1. 
Serious and Unanticipated Adverse Device Effects for Abaloparatide-SC 
An adverse device effect (ADE) is defined as any adverse event related to the use of an 
investigational medical device (IMD). For the purposes of this protocol, abaloparatide-SC is the 
IMD. All ADEs should be reported as an AE per Section 7.1, which includes AEs resulting from 
insufficient or inadequate instructions for use, deployment, implantation, installation, operation, 
any malfunction of the IMD, use error, or intentional misuse of the IMD (ISO/DIS 14155). 
An unanticipated adverse device effect (UADE) is defined as any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the 
abaloparatide-SC device, if that effect, problem, or death was not previously identified in nature, 
severity, or degree of incidence in the application/IB, or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects (21 CFR 
812.3(s)). 
Any UADE that occurs during the study from the time the subject signs the ICF until 30 days 
after the last dose of study medication must be reported within 24 hours of first awareness of the 
event using the SAE and the UADE report forms and emailing to PV@radiuspharm.com. 
The Investigator and the Sponsor will immediately conduct an evaluation of any UADE 
occurring with abaloparatide-SC. The results of the evaluation will be reported to the IRB within 
10 days of the Sponsor becoming aware of the event. 
If it is determined by the Investigator and the Sponsor to present an unreasonable risk to study 
subjects, all investigations or parts of the investigation presenting that risk will be terminated as 
soon as possible. Termination will occur not later than 5 working days after the Investigator and 
the Sponsor makes this determination and not later than 15 working days after the Sponsor first 
receiving notice of the event. The Investigator and the Sponsor will not resume an investigation 
terminated under these conditions without an additional IRB approval. 
7.1.4. 
Serious Adverse Event Reporting 
Any SAEs that occur during the study from the time the subject signs the ICF until 30 days after 
the last dose of study medication must be reported within 24 hours of first awareness of the event 
using the SAE report form and emailing to PV@radiuspharm.com. Data should also be entered 
in the clinical trial eCRF. 
Treatment-related SAEs will be followed until resolution or stabilization. The reference safety 
information for this study is the IB, which will be provided under separate cover to all 
Investigators. 
Any SAEs that occur at any time after completion of the study, which the Investigator considers 
to be related to study drug, must be reported to the Sponsor or its designee. 
The Investigator must submit the SAE to the IRB/ IEC in accordance with 21 CFR parts 56 and 
312 as well as with applicable local regulations. Documentation of these submissions must be 
retained in the site study file. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 68 of 81 
7.1.5. 
Device Reporting 
Abaloparatide-SC is a drug-device combination product. In order to fulfill regulatory reporting 
obligations worldwide, the Investigator is responsible for the detection and documentation of 
events meeting the definition of a UADE that occurs with abaloparatide-SC (Section 7.1.3.1). 
Any UADEs that occur during the study with abaloparatide-SC, from the time the subject signs 
the ICF until 30 days after the last dose of study drug, must be reported within 24 hours of first 
awareness that the event meets the definition of a reportable incident by entering data in the 
clinical trial eCRF. Treatment-related UADEs will be followed until resolution or stabilization, 
the condition is otherwise explained, or until the subject is lost to follow-up. 
SAEs (initial reports and follow-up information) must be reported by the Investigator using the 
SAE report form; the form must be completed and emailed to PV@radiuspharm.com. 
The Investigator will comply with the applicable local regulatory requirements relating to 
reporting to the IRB/IEC. 
7.1.6. 
Follow-up of Adverse Events 
All treatment-related AEs will be followed with appropriate medical management until resolved 
or stabilized. 
UADEs will be followed until their medical outcome is determined, with periodic written reports 
about the status provided to the Sponsor. 
7.1.7. 
Abuse, Misuse, Overdose, or Medication Error 
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the Sponsor 
whether or not they result in an AE/SAE. 
• Abuse – Persistent or sporadic intentional intake of investigational medicinal product 
at a dose higher than prescribed per protocol (but below the dose defined for 
overdose) or when used for non-medical purpose (e.g., altering one’s state of 
consciousness). 
• Misuse – Intentional or unintentional use of investigational medicinal product other 
than as directed or indicated at any dose, which is at or below the dose defined for 
overdose Note: this includes a situation where the test article is not used as directed at 
the dose prescribed by the protocol. 
• Overdose – Intentional or unintentional injection of a dose of abaloparatide at least 
2 times higher than the protocol-specified dose and is associated with clinical 
symptoms. 
• Medication Error – A mistake made in prescribing, dispensing, administration and/or 
use of the investigational medicinal product. 
7.1.8. 
Pregnancy 
Any pregnancy for the partner of a study participant must be reported on the Partner’s Pregnancy 
Report Form within 24 hours and emailed to the RADIUS Pharmacovigilance Department at 
PV@radiuspharm.com. Every effort should be made to gather information regarding the 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 69 of 81 
pregnancy outcome. It is the responsibility of the Investigator to obtain this information within 
30 calendar days after the initial notification and approximately 30 calendar days postpartum. 
In subjects who have partners of childbearing potential, the subject and his partner should abstain 
from sexual intercourse, or use highly effective contraceptive measures (e.g., oral contraceptive 
and condom, IUD and condom, or diaphragm with spermicide and condoms; other forms of 
contraception must be approved by a Medical Monitor) when engaging in sexual intercourse 
throughout the study, and for at least 90 days after the last dose of abaloparatide. 
7.1.9. 
Regulatory Agency, Institutional Review Board, Ethics Committee and Site 
Reporting 
The Sponsor and/or the clinical contract research organization (CRO) are responsible for 
notifying the relevant regulatory authorities/US central IRBs/EU central IEC committees of 
related, unexpected SAEs. 
The Investigator is responsible for notifying the Sponsor, CRO, and local IRB/IEC, or the 
relevant local regulatory authority of all SAEs that occur at his or her site as required. 
If a death occurs during the study or within 30 days after Month 12/Early Termination visit 
(Visit 8), and it is determined to be related either to a study procedure or a study drug, the 
Investigator or his/her designee must notify the Sponsor and will communicate that information 
to the IRB/IEC within one business day of knowledge of the event. The contact may be by phone 
or email. 
7.2. 
Study Completion and Post-Study Treatment 
The Investigator must provide follow-up medical care for all subjects who are prematurely 
withdrawn from the study due to an adverse event or must refer them for appropriate ongoing 
care. 
7.3. 
Lost to Follow-up 
For subjects whose status is unclear because they fail to appear for study visits without stating an 
intention to discontinue or withdraw, the Investigator should show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g., dates of telephone 
calls, registered letters. A subject should not be formally considered lost to follow-up until 
multiple attempts to contact the subject have been made, including at least 2 attempts to reach 
the subject by phone followed by a certified letter sent to the subject’s last known mailing 
address.  
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 70 of 81 
8. 
STATISTICAL CONSIDERATIONS 
8.1. 
Statistical and Analytical Plans 
A comprehensive SAP will be completed and approved prior to database lock. All statistical tests 
will be 2-sided with a significance level of 1%, unless otherwise specified. 
8.2. 
Statistical Hypotheses 
The primary objective of this study is to evaluate the efficacy and safety of abaloparatide-SC 
80 µg per day compared to placebo in men with osteoporosis. The hypotheses to be tested are 
that abaloparatide is superior to placebo, and that the safety profile of abaloparatide-SC in 
osteoporotic men is similar to that of abaloparatide-SC in postmenopausal women with 
osteoporosis. 
8.3. 
Analysis Datasets 
8.3.1. 
Populations for Analysis 
The primary population for all efficacy analyses will be the Intention-to-Treat (ITT) Population, 
which is defined as all subjects randomized into this study. The primary population for safety 
analyses will be the Safety Population, defined as all subjects who received at least one dose of 
study medication. The Per-Protocol (PP) Population will include all ITT subjects who did not 
have any significant protocol deviations and will be used for supportive analyses. The criteria for 
the exclusion from the PP Population will be appropriately documented prior to database lock 
and treatment unblinding.  
8.4. 
Description of Statistical Methods 
8.4.1. 
General Approach 
Analyses will be presented by treatment group (abaloparatide-SC and placebo) and overall, when 
appropriate. Baseline is defined as the last value obtained prior to the first dose of study 
medication. 
For categorical data, summary tabulations of the number and percentage of subjects within each 
category of the parameter will be presented. For continuous data, the number of subjects, mean, 
median, standard deviation (SD), minimum, interquartile range (Q1 and Q3), and maximum will 
be presented. 
8.4.2. 
Analysis of the Primary Efficacy Endpoint(s) 
The primary efficacy endpoint will be the percent change in lumbar spine BMD from baseline to 
12 months. The analyses will be based on the ITT Population.  
The missing data from this study will be reviewed carefully to evaluate any missing data 
patterns. As this study was not designed to systematically collect data from subjects who 
discontinue treatment early, the “retrieved dropouts” approach for handling missing data is not 
applicable for this study. To appropriately address the possibility of data missing not at random, 
the primary analysis will be based on a pattern-mixture model (PMM) analysis with multiple 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 71 of 81 
imputation using the wash-out imputation method. This method uses sequential regression and 
wash-out imputation methodology to impute missing values after a subject’s discontinuation 
from the study. The missing primary endpoint values for subjects in the abaloparatide-SC group 
will be imputed with the observed baseline and data from the placebo group; no intermediate 
values from the abaloparatide-SC group will be used in the imputation for the abaloparatide-SC 
group. For subjects in the placebo group, intermediate observed values from the completers in 
the placebo group will be used while imputing missing values during the 12-month Treatment 
Period. The PROC MI methodology for imputation of monotone missing data patterns will be 
used to impute the outcome variables at consecutive visits in a sequential (chain) manner. Each 
of these imputed datasets will be analyzed using analysis of covariance (ANCOVA) with 
treatment and DXA instrument manufacturer as fixed effects and the baseline lumbar spine BMD 
as a covariate. Results from all imputed datasets will be combined using PROC MIANALYZE 
for overall statistical inference. The statistical tests will be 2-sided comparing abaloparatide-SC 
to placebo; 99% CIs will be presented together with the estimated p-values.  
As a sensitivity analysis, the primary efficacy endpoint will also be analyzed using a Mixed 
Model for Repeated Measures (MMRM) analysis. The MMRM model will include the fixed 
effects of treatment, DXA instrument manufacturer, visit, and treatment-by-visit interaction, with 
the baseline lumbar spine BMD as a covariate. For the MMRM model, an unstructured variance-
covariance matrix shared between the 2 treatment groups will be used to model the within-
subject errors over the visits. The treatment comparison will be obtained by testing the contrast 
(difference in least squares mean) between the 2 treatment groups at Month 12 (Visit 8). The 
statistical tests will be 2-sided comparing abaloparatide-SC to placebo; 99% CIs will be 
presented together with the estimated p-values. 
Sensitivity analyses for addressing the effect of the COVID-19 pandemic and supportive 
analyses using the last observation carried forward (LOCF) method to impute missing data will 
also be conducted.  
8.4.3. 
Analysis of Secondary Endpoint(s) 
The key secondary efficacy endpoints are: 
• Percent change from baseline in total hip BMD at 12 months 
• Percent change from baseline in femoral neck BMD at 12 months 
Additional secondary efficacy endpoints are: 
• Percent change from baseline in: 
− Lumbar spine BMD at 3 and 6 months 
− Total hip BMD at 3 and 6 months 
− Femoral neck BMD at 3 and 6 months 
− Ultra-distal radius BMD at 3, 6, and 12 months 
− Distal one-third radius BMD at 3, 6, and 12 months 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 72 of 81 
• Log ratio of post-baseline over baseline in: 
− s-PINP at 1, 3, 6, and 12 months 
− s-CTX at 1, 3, 6, and 12 months 
• Proportion of subjects experiencing BMD gains from baseline of > 0%, > 3%, and 
> 6% at the lumbar spine, femoral neck, and total hip at 3, 6, and 12 months 
• Incidence of new clinical fractures at 12 months 
• Proportion of subjects converting from the categories of osteoporosis to osteopenia or 
to normal at 12 months, where: 
− Osteoporosis is defined as lumbar spine or total hip BMD T-score ≤ -2.5.  
− Osteopenia is defined as one of the following: 
o Lumbar spine > -2.5 and total hip BMD T-score > -2.5 and < -1.0 
o Lumbar spine > -2.5 and < -1.0 and total hip BMD T-score > -2.5  
− Normal is defined as lumbar spine and total hip BMD T-score ≥ -1.0.  
• The percent change in total hip and femoral neck volumetric BMD as measured by 
QCT from baseline to 12 months. QCT will be performed in a subset of subjects at a 
selected number of study sites. 
Analyses of the primary and key secondary endpoints will follow a fixed-sequence testing 
approach to control the overall Type 1 error rate at the 2-sided significance level of 1%. To claim 
statistical significance at the 2-sided level of 1%, the following 3 fixed-sequence tests will be 
performed in sequential order. At any step of the sequential testing, if the treatment difference is 
not statistically significant at the 1% level then all the subsequent comparisons following the 
fixed sequence cannot be claimed statistically significant. 
1. Percent change from baseline in BMD at the lumbar spine at 12 months 
2. Percent change from baseline in BMD at the total hip at 12 months 
3. Percent change from baseline in BMD at the femoral neck at 12 months 
P-values for treatment comparisons of all other efficacy endpoints will be generated to support 
the study findings without any adjustments for multiplicity. 
The analyses of the key secondary BMD endpoints will be performed using a PMM analysis 
with multiple imputation using the wash-out imputation method similar to the analysis for the 
primary efficacy endpoint, as stated in Section 8.4.2, with the appropriate baseline covariate. 
Sensitivity analyses using MMRM models, sensitivity analyses for addressing the effect of the 
COVID-19 pandemic, and supportive analyses using the LOCF method, as with the primary 
efficacy endpoint, will also be conducted. 
The bone formation marker, s-PINP, and the bone resorption marker, s-CTX, will be analyzed 
based on the ratio of the post-baseline value relative to the baseline using a natural log 
transformation at each visit. The analysis will use a PMM analysis with multiple imputation 
using the wash-out imputation method similar to that described in Section 8.4.2. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 73 of 81 
Percent changes from baseline in BMD over time will be summarized using descriptive statistics 
by visit for each treatment group. 
The bone formation marker, s-PINP, and the bone resorption marker, s-CTX, will be 
summarized descriptively by treatment group, with values, changes and percent changes from 
baseline, geometric mean values, and geometric mean values relative to baseline at each visit. 
A BMD responder analysis by visit will be performed for those subjects who have both baseline 
and the relevant post-baseline BMD values. Three categories of BMD response will be 
evaluated: %BMD increase > 0%, > 3%, and > 6%. The response will be assessed at the lumbar 
spine, total hip, and femoral neck. Subjects who have BMD increase at all 3 skeletal sites at the 
same visit will be considered responders, with the primary time point at 12 months. No 
imputation of missing data will be implemented. The number and percentage of responders in 
each treatment group will be compared using either the Chi-square test or Fisher’s exact test. 
Kaplan-Meier estimates for the time to new clinical fracture at 12 months and the hazard ratio 
(99% CI) will be presented, with treatment comparisons based on the log-rank test. 
The number and percentage of subjects for whom disease status (categories as defined in the 
secondary endpoints listed earlier in this section) has changed from osteoporosis at baseline to 
osteopenia, normal, or no change at 12 months will be analyzed using the Chi-square test. 
The percent change from baseline in total hip and femoral neck volumetric BMD (vBMD) at 
12 months, as measured by quantitative CT will be analyzed using a similar ANCOVA model as 
stated in Section 8.4.2. 
The primary analyses of the secondary efficacy variables will be based on the ITT Population 
and will be repeated using the PP Population. 
Subgroup analysis (e.g., age, geography, FRAX, prior fracture, and baseline BMD, s-PINP, 
testosterone, and estradiol levels) may be performed. Details of the subgroup analyses will be 
described in the SAP. 
8.4.4. 
Pharmacokinetic Analyses 
A population PK analysis will be performed on the sparse plasma concentration data of 
abaloparatide as described in the Pharmacometric Analysis Plan. This analysis may be expanded 
to include a population PK/exposure-response analysis of the percent change in BMD from 
baseline over time. 
8.4.5. 
Safety Analyses 
Unless otherwise specified, safety analyses will be conducted using the Safety Population and 
will be descriptive in nature. 
Study drug exposure and study drug compliance will be calculated. The duration of study drug 
exposure, total dose received, and percent compliance will be summarized by treatment group. 
All AEs will be coded using MedDRA. The number and percent of subjects who experienced 
TEAEs will be summarized by MedDRA system organ class (SOC), preferred term, and 
treatment group. Summaries will also be provided for severe TEAEs, SAEs, TEAEs leading to 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 74 of 81 
study drug withdrawal, drug-related TEAEs (with probable or possible relationship to study 
drug), and TEAEs by maximum severity (mild, moderate, severe). 
The number and percent of subjects who report TEAEs associated with hypercalcemia and 
hypercalciuria will be summarized by treatment group. 
All AEs collected prior to the first dose of study drug will be summarized separately. 
A listing of subjects who experience an UADE will be provided. 
Descriptive statistics for laboratory data (including serum calcium and albumin), vital signs 
(including orthostatic blood pressure [BP]), ECGs, Investigator assessment of local tolerance, 
and subject assessment of local tolerance will be provided by treatment group and visit. For 
laboratory data, vital signs, and ECGs, absolute results and changes from baseline will be 
presented. In addition, laboratory test results will be classified as above normal limit, within 
normal limit, or below normal limit. Laboratory shift frequencies will be tabulated between the 
Screening Visit and relevant post-baseline visit(s). 
For subjects in the abaloparatide-SC group, the anti-abaloparatide antibody assessment in the 
serum samples for immunogenicity testing will be categorized by 2 outcomes: 
• Negative for anti-abaloparatide antibodies 
• Positive for anti-abaloparatide antibodies 
The number (%) of subjects in the above categories of abaloparatide antibodies will be 
summarized on Day 1 (Visit 3) and at Month 1 (Visit 4), Month 3 (Visit 5), Month 6 (Visit 6), 
Month 9 (Visit 7), Month 12 (Visit 8), and the Follow-up Visit scheduled approximately 1 month 
after the last dose of study medication (Visit 9) using the Antibody Population.  
For those subjects with a positive anti-abaloparatide antibody present, the titer level, presence of 
neutralizing anti-abaloparatide antibodies (negative or positive), and assessment outcomes for 
cross-reactivity to PTH (negative or positive) and PTHrP antibodies (negative or positive), 
together with the neutralizing antibody status in subjects that are positive for PTH (negative or 
positive for the presence of PTH-neutralizing antibodies) or PTHrP (negative or positive for the 
presence of PTHrP-neutralizing antibodies), will be summarized by study visit.  
The results of antibody analyses will be included in a separate report. 
Concomitant medications will be coded using the World Health Organization (WHO) Drug 
Dictionary and summarized by number and percentage of subjects using each class and preferred 
drug term by treatment group. 
8.4.6. 
Adherence and Retention Analyses 
The number and percentage of subjects who withdraw from the study, with primary reason, will 
be summarized by treatment group. 
8.4.7. 
Baseline Descriptive Statistics 
Medical history, physical examination, demographics, and baseline characteristics will be 
summarized and presented by treatment group and overall. Medical history will be presented by 
MedDRA SOC and PT, summarizing the proportion of subjects who have a condition noted. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 75 of 81 
Results from the baseline physical examination will be summarized by body system as recorded 
in the eCRF.  
8.4.8. 
Interim Analyses 
There are no interim analyses planned for this study.  
8.4.9. 
Additional Subgroup Analyses 
Subgroup analysis (e.g., age, geography, FRAX (if applicable), prior fracture, and baseline 
BMD, s-PINP, testosterone, and estradiol levels) may be performed and will be described in the 
SAP. 
8.4.10. 
Multiple Comparison/Multiplicity 
As stated in Section 8.4.3, a fixed-sequence testing approach will be employed to control the 
Type 1 error rate at the 2-sided significance level of 1% for testing the primary and secondary 
efficacy endpoints. No other adjustments for multiple comparisons will be made. 
8.4.11. 
Tabulation of Individual Response Data 
Individual efficacy, PK, and safety data will be tabulated as appropriate. 
8.4.12. 
Exploratory Analyses 
Prespecified exploratory variables and analyses are described in Section 8.4.3. 
8.5. 
Sample Size Calculation 
A study sample size of 225 subjects (150 in the abaloparatide-SC group and 75 in the placebo 
group) will provide at least 99% power to detect a mean difference of 6.5% in the percentage 
change from baseline in lumbar spine BMD at 12 months between the abaloparatide-SC and the 
placebo groups at a 2-sided alpha level of 0.01, assuming a SD of 6.0% and a drop-out rate of 
10%. For the key secondary endpoints, this total sample size of 225 subjects will have 96% 
power to detect a 2.2% mean difference (SD = 3.5%) of percent change in total hip BMD at 
12 months, and 80% power to detect a 2.0% mean difference (SD = 4.1%) of percent change in 
femoral neck BMD at 12 months. 
8.6. 
Measures to Minimize Bias 
Not applicable. 
8.7. 
Enrollment/Randomization/Masking Procedures 
Abaloparatide-SC and placebo study medications will be prepared in a blinded fashion. Data will 
be reviewed in a blinded fashion and the analysis populations defined prior to database lock and 
unblinding. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 76 of 81 
9. 
ADMINISTRATIVE REQUIREMENTS 
9.1. 
Ethical Considerations 
This clinical study will be conducted in accordance with the current version of the ICH 
Harmonized Guideline for Good Clinical Practice (GCP), with applicable local laws and 
regulations, and with the ethical principles laid down in the Declaration of Helsinki. 
The Investigator will ensure that this study is conducted in full conformity with ICH GCP 
E6(R2). 
The IRB/IEC will review all appropriate study documentation to safeguard the rights, safety, and 
well-being of the subjects. The study will only be conducted at sites where IRB/IEC approval has 
been obtained. The protocol, IB, ICF, advertisements (if applicable), written information given to 
the subjects, safety updates, annual progress reports, and any revisions to these documents will 
be provided to the IRB/IEC by the Investigator or RADIUS or designee, as allowable by local 
applicable laws and regulations. 
9.2. 
Subject Information and Informed Consent 
The Investigator is responsible for obtaining written, informed consent from each subject 
interested in participating in this study before conducting any study-related procedures. 
Written informed consent should be obtained after adequate, thorough, and clear explanation of 
the study objectives, procedures, as well as the potential hazards of the study. The method of 
obtaining and documenting the informed consent and the contents of the consent will comply 
with ICH GCP and all applicable laws and regulations and will be subject to approval by 
RADIUS or its designee. 
9.3. 
Investigator Compliance 
No modifications to the protocol should be made without the approval of both the Investigator 
and RADIUS. Changes that significantly affect the safety of the subjects, the scope of the 
investigation, or the scientific quality of the study (i.e., efficacy assessments) will require 
IRB/IEC notification before implementation, except where the modification is necessary to 
eliminate an apparent immediate hazard to human subjects. RADIUS will submit all protocol 
modifications to the required regulatory authorities. 
When circumstances require an immediate departure from procedures set forth in the protocol, 
the Investigator will contact RADIUS to discuss the planned course of action. If possible, contact 
should be made before the implementation of any changes. Any departures from protocol must 
be fully documented in the source documentation. 
9.4. 
Access to Records 
The Investigator must make the office and/or hospital records of subjects enrolled in this study 
available for review by site monitors at the time of each monitoring visit, audit by RADIUS 
Quality Assurance (QA) and inspection by the regulatory agencies. The records must also be 
available for inspection, verification, and copying, as required by applicable laws and 
regulations, by officials of the regulatory health authorities (FDA and others). The Investigator 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 77 of 81 
must comply with applicable privacy and security laws for use and disclosure of information 
related to the research set forth in this protocol. 
9.5. 
Subject and Data Confidentiality 
To maintain subject confidentiality, all eCRFs, study reports and communications relating to the 
study will identify subjects by assigned subject numbers. As required by federal regulations, the 
Investigator will allow RADIUS and/or its representatives access to all pertinent medical records 
to allow for the verification of data gathered in the eCRFs/SAE Forms and the review of the data 
collection process. The FDA (or other regulatory authority) may also request access to all study 
records, including source documentation, for inspection. 
As applicable, in accordance with the Health Insurance Portability and Accountability Act 
(HIPAA) and associated privacy regulations, a subject authorization to use personally 
identifiable health information may be required from each subject before research activities 
begin. 
Subject confidentiality is strictly held in trust by the participating Investigators, their staff, and 
RADIUS and their representatives. This confidentiality is extended to cover testing of biological 
samples and genetic tests in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be 
held in strict confidence. No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of RADIUS. 
9.6. 
Research Use of Stored Human Samples, Specimens, or Data 
With the subject’s approval, and as approved by the site’s IRB/IEC, biological samples may be 
stored at a centralized facility determined by RADIUS. These samples could be used for 
retrospective biomarker research or analysis of clinical response to therapy and to improve 
current and future treatment outcomes. The storage facility will maintain the masking of the 
identity of the subject. 
During the conduct of the study, any individual subject can choose to withdraw consent to have 
biological specimens stored for future research. When the study is completed, access to study 
data and/or samples will be provided through RADIUS. 
9.7. 
Data Quality Assurance 
RADIUS or its designated representative will conduct a study site visit to verify the 
qualifications of each Investigator, inspect clinical study site facilities as needed, and inform the 
Investigator of responsibilities and procedures for ensuring adequate and correct study 
documentation. 
The Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertinent to the study for each study subject. 
Study data for each enrolled subject will be entered into an eCRF by site personnel using a 
secure, validated web-based electronic data capture (EDC) application. RADIUS will have read-
only access to all data upon entry in the EDC application. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 78 of 81 
Instances of missing, discrepant, or uninterpretable data will be queried with the Investigator for 
resolution. Any changes to study data will be made to the eCRF and documented in an audit trail, 
which will be maintained within the clinical database. 
To ensure compliance with GCP and all applicable regulatory requirements, a quality assurance 
audit may be conducted. Regulatory agencies may also conduct a regulatory inspection of this 
study. Such audits/inspections can occur at any time during or after completion of the study. If an 
audit or inspection occurs, the Investigator and institution agree to allow the auditor/inspector 
direct access to all relevant documents and to allocate his/her time and the time of his/her staff to 
the auditor/inspector to discuss findings and any relevant issues. In the case of an audit or 
inspection, the Investigator or a delegate will alert RADIUS, as soon as he/she becomes aware of 
the audit or inspection. 
The Investigator and study staff are responsible for maintaining a comprehensive and accurate 
filing system of all study-related documentation that will be suitable for inspection at any time 
by RADIUS, its designees, and/or regulatory agencies. In signing this protocol, the Investigator 
understands and agrees to give access to the necessary documentation and files. 
9.8. 
Monitoring 
RADIUS is responsible for ensuring the proper conduct of the study with regard to protocol 
adherence and validity of data recorded in the clinical database. The study will be monitored by 
RADIUS or its designee. Monitoring will be done by personal visits from a representative of 
RADIUS, or designee (site monitor), who will review the eCRFs, SAE Forms and source 
documents. The site monitor will ensure that the investigation is conducted according to the 
protocol design and regulatory requirements. 
9.9. 
Data Collection and Management Responsibilities 
Data collection is the responsibility of the clinical study staff at the site under the supervision of 
the Investigator. The Investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported. 
RADIUS will provide the study sites with secure access to and training on the EDC application 
sufficient to permit site personnel to enter and correct information in the eCRFs on the subjects 
for which they are responsible for.  
An eCRF will be completed for each subject who receives at least one dose of study drug. It is 
the Investigator's responsibility to ensure the accuracy, completeness, clarity, and timeliness of 
the data reported in the subject’s eCRF. Source documentation supporting the eCRF data should 
indicate the subject’s participation in the study and should document the dates and details of 
study procedures, AEs, other observations, and subject status. 
The Investigator, or designated representative, should complete the eCRF in a timely manner 
after information is collected. 
The audit trail entry will show the user's identification information and the date and time of any 
correction. The Investigator must provide formal approval of all the information in the eCRFs, 
including any changes made to the eCRFs, to endorse the final submitted data for the subjects for 
whom the Investigator is responsible. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 79 of 81 
RADIUS will retain the eCRF data, queries, and corresponding audit trail. A copy of the final 
archival eCRF in the form of a compact disc or other electronic media will be provided to the site 
for placement in the Investigator's study file. 
9.10. 
Study Records Retention 
The Investigator will maintain study documents for a minimum of 2 years after the last approval 
of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents should 
be retained for a longer period, however, if required by local regulations. If the Investigator 
withdraws from the responsibility of keeping the study records, custody must be transferred to a 
person willing to accept the responsibility and RADIUS must be notified. No records will be 
destroyed without the written consent of RADIUS. 
9.11. 
Publication and Data Sharing Policy 
Publication of complete data from the study is planned. It is anticipated that the results of this 
study will be presented at scientific meetings and/or published in a peer reviewed scientific or 
medical journal. A Publications Committee composed of Investigators participating in the study 
and representatives from RADIUS as appropriate will be formed to oversee the publication of the 
study results, which will reflect the experience of all participating study sites. 
Subsequently, individual Investigators may publish results from the study in compliance with 
their agreement with RADIUS. 
 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 80 of 81 
10. 
LITERATURE REFERENCES 
Bilezikian JP. Anabolic therapy for osteoporosis. Women’s Health (Lond). 2007;3:243-253. 
Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid 
hormone on bone. Endocr Rev. 1993;14:690–709. 
Ebeling PR. Osteoporosis in men. New Engl J Med. 2008;358:1474-1482. 
Food and Drug Administration (FDA). FDA Guidance on Conduct of Clinical Trials of Medical 
Products During the COVID-19 Public Health Emergency. 2021; accessed via 
https://www.fda.gov/media/136238/download 
Genant HK, Wu CY, van Kuijk KC, Nevitt MC. Vertebral fracture assessment using a 
semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148. 
Hattersley G, Dean T, Corbin BA., Bahar H, Gardella TJ. Binding selectivity of abaloparatide for 
PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 
2016;157:141-49. 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) Guideline for Industry - Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting (ICH E2A). 1995 
International Organization of Standardizations. (2018). Clinical investigation of medical devices 
for human subjects — Good clinical practice, ISO/DIS 14155. 
https://www.iso.org/obp/ui/#iso:std:iso:14155:dis:ed-3:v1:en. Accessed 11-Nov-2019 
International Osteoporosis Foundation. Osteoporosis in men. 2014; accessed via 
http://www.iofbonehealth.org/WOD/2014/thematic-report/WOD14-Report.pdf 
Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocrine Rev. 2008;29:441-464. 
Litwic A, Lekarz, Warwick D, Denniston E. Distal radius fracture: Cinderella of the osteoporotic 
fractures. Orthop Muscul Syst. 2014; 3:162-8. 
Makino M, Takagi H, Sugiyama H, Kobayashi T, Kasahara Y. Effects of abaloparatide on the 
expression of bone resorption and formation-related factors in osteoblastic cells; a comparison 
with teriparatide. Annual Meeting of the American Society for Bone and Mineral Research 2015; 
MO0121. 
Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: Their biological 
importance and functional properties. Am J Physiol. 1999; 277:F665-F675 
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, 
Hu M, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C. Effect of abaloparatide vs placebo 
on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical 
trial. J Am Med Assoc. 2016;316:722-733. 
Newcombe RG. Interval estimation for the difference between independent proportions: 
Comparison of eleven methods. Stat Med. 1998; 17:873-890. 
Rizzoli R. Osteoporosis, genetics and hormones. J Mol Endocrinol. 2001;26:79-94. 
Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353:595-603. 

Radius Health, Inc. 
Abaloparatide-SC  
Confidential 
Study BA058-05-019 Amendment 6 
 
Page 81 of 81 
WHO. Assessment of osteoporosis at the primary health care level. Summary of a WHO 
Scientific Group 2007 [16 Feb 2017]. Available from: 
www.who.int/chp/topics/rhuematicrheumatic/en/index.html 

Signature Page for RAD-CLIN-000847 v8.0
Signature Page for RAD-CLIN-000847 v8.0
Approval
31-Mar-2021 13:36:14 GMT+0000
Approval
31-Mar-2021 13:50:41 GMT+0000
Approval
31-Mar-2021 15:57:03 GMT+0000
Approval
31-Mar-2021 22:38:39 GMT+0000